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Besides neurons, the central nervous system (CNS) consists of glial cells, 
which are mainly microglia and astrocytes. Chronic pain is classically viewed as 
being mediated solely by neurons, but there is mounting evidence that glial cells 
also play a part. Glial cells, responding to stimulation by neurotransmitters and 
peptides, are activated and release pain-enhancing substances like pro-
inflammatory cytokines. These cytokines have been shown to play a role in 
enhancing pain by their actions in the spinal cord. 
This research work focuses firstly on investigating pro-inflammatory 
cytokine release in a cell culture system as a potential marker for chronic pain. 
Two conditions related to chronic pain were studied: post-herpetic neuralgia 
(PHN) and osteroarthritis. Cerebrospinal fluid (CSF) from patients suffering from 
either condition was used to trigger astrocytic cell line T98G cultures, and 
subsequent pro-inflammatory cytokine release was measured by enzyme-linked 
immunosorbent assay (ELISA). IL-6 release in the chronic pain patient groups 
was found to be significantly higher compared to pain-free controls, as well as in 
the PHN patient group whose steroid treatment was ineffective compared to those 
whose treatment was effective. CSF samples collected before steroid treatment 
also triggered higher IL-6 release than after treatment samples. These in vitro tests 
provide an objective evaluation on the extent of chronic pain as well as the 
efficacy of steroid therapy. 
  
x 
Secondly, we attempted to separate and isolate pain-related substances in 
chronic pain patients’ CSF, making use of the in vitro T98G cell system 
established earlier. The CSF was separated by a two-step high performance liquid 
chromatography (HPLC) technique, and the fractions that triggered IL-6 release 
in T98G cells were isolated. We narrowed down to three peaks that could trigger 
IL-6 release and these peaks would be subjected to future mass spectrometry 
analysis to identify the protein-like substances in the CSF, which could be 
potential markers for chronic pain. Lastly, we attempted to elucidate the IL-6 
signaling pathway in this in vitro model of chronic pain. NF-κB inhibition studies 
and western blot analysis confirmed that NF-κB acts upstream of IL-6 in this 
T98G cell system. 
In conclusion, we have established an effective in vitro assay system to 
quantify chronic pain utilizing CSF and have taken the first steps in isolating 
pain-related protein substances in the CSF of chronic pain patients. In an attempt 
to better understand the complex mechanisms, we hope to contribute to the 
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1.1 Chronic Pain 
The International Association for the Study of Pain defines chronic pain as 
pain that persists for at least 3 months. Chronic pain is normally triggered by 
injury or disease, which damages the nervous system in such a way that it is 
unable to restore its normal physiological functions to homeostatic levels. It can 
persist for months or years, long after the original injury has healed (Gao and Ji, 
2010). Chronic pain is heterogeneous, and multiple molecular and cellular 
mechanisms act in combination within the peripheral nervous system (PNS) and 
central nervous system (CNS) to produce the chronic pain (Scholz and Woolf, 
2002). 
 
 1.1.1 Epidemiology of Chronic Pain 
Chronic pain has become a major healthcare challenge as it interferes with 
normal daily life. The World Health Organization (WHO) approximates that one 
in five people worldwide experiences chronic pain. In a large-scale survey 
involving 16 countries, 19% of respondents over 18 years old had suffered pain 
for more than 6 months. 61% of these chronic pain sufferers were unable to work 
outside the home, and 19% had lost their jobs. 40% of them had insufficient pain 
management and only 2% were seeing a pain specialist (Breivik et al., 2006). 
A study carried out in Singapore in 2009 showed that the prevalence of 
chronic pain was 8.7%. Chronic pain afflicted women at a higher rate than men, 
and the prevalence increased sharply beyond 65 years of age. Although a 
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seemingly lower prevalence of chronic pain was seen in this study, it remains a 
healthcare problem of high importance, due to a rapidly ageing population in 
many developed countries including Singapore, and is likely to consume an 
increasingly large amount of healthcare resources within the next few years (Yeo 
and Tay, 2009).  
 
1.1.2 Pathophysiology of Chronic Pain 
Chronic pain can be classified as either nociceptive or neuropathic. 
Nociceptive pain is derived from mechanical, chemical or thermal irritation to the 
peripheral sensory nerves, and is typically well-localized. Neuropathic pain, on 
the other hand, is pain initiated by damage to or a lesion of the nervous system, 
and is characterized by poor localization (Goucke, 2003). 
Chronic pain results from the development of neural plasticity in the PNS 
and CNS. It was traditionally believed that only neurons and their neural circuits 
were responsible for pain development and maintenance. Hence current 
therapeutics for chronic pain focuses on neuronal targets, which include N-
methyl-D-aspartic acid (NMDA) receptor antagonists and opioid analgesics. Such 
therapies provide transient pain relief and do not resolve the underlying 
pathological processes that lead to chronic pain. Hence, studies on non-neuronal 
cells, in particularly glial cells in chronic pain conditions, have increased 




1.1.2.1 Role of Glial Cells in Chronic Pain 
Recent studies and review articles have highlighted a communication 
cross-talk that exists between the immune system and the nervous system (Scholz 
and Woolf, 2007). Neurons and glial cells in the nervous system have close 
interactions with each other on a cellular and molecular level. Injury to peripheral 
nerves triggers an inflammatory response in peripheral glia and immune cells. The 
vital role of inflammation in the development of chronic pain is demonstrated in a 
study whereby injection of pro-inflammatory agents such as carrageenan or 
complete Freund’s adjuvant around the sciatic nerve induced mechanical 
allodynia in animal models (Sorkin and Schafers, 2007). The peripheral 
inflammatory response then sets off a series of downstream reactions through the 
release of neurotransmitters or neuromodulators from primary afferents. These 
substances in turn lead to activation of glial cells that are in close proximity to the 
afferent neuron terminals (Vallejo et al., 2010).  
Glial cells, forming 70% of the total cell population in the brain and spinal 
cord, have long been viewed as performing mainly neuronal housekeeping and 
support functions, providing insulation and protection to the neurons. They do not 
have axons, and hence they have been perceived to have no role in nerve signal 
transmission. However, this view has slowly been changing. Pathological pain is 
classically viewed as being mediated solely by neurons, but there is mounting 
evidence that glial cells also play a part in exaggerated pain states created by 
inflammation and neuropathy (Hashizume et al., 2000; Watkins and Maier, 2002). 
Astrocytes, in particular, play an important role in pain processing. They are the 
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most abundant cells in the CNS (constituting 40-50% of all glial cells) in terms of 
number and volume, forming networks with themselves via gap junctions and 
making very close contacts with neuronal synapses and blood vessels (Halassa et 
al., 2007). Astrocytes express receptors for numerous neurotransmitters, 
neuroactive substances and amino acids, and hence provide support and 
nourishment for neurons as well as regulate the external chemical environment 
during synaptic transmission (Verkhratsky and Steinhauser, 2000; Hanson and 
Ronnback, 2004).  
In normal physiological conditions, glial cells are in a quiescent state. In 
most cases of early glial response to injury or disease conditions, activation of 
microglia occurs first. Activated microglia display a change in surface markers 
and membrane proteins, and this triggers the production and release of pain-
enhancing substances such as reactive oxygen species, excitatory amino acids, 
nitric oxide, prostaglandins and pro-inflammatory cytokines (Wieseler-Frank, 
Maier and Watkins, 2004). This subsequently leads to activation and proliferation 
of astrocytes, correlating with the release of even more pain enhancing substances. 
These substances modulate pain processing by influencing either presynaptic 
release of neurotransmitters and/or postsynaptic excitability, leading to 
persistence in hypersensitivity and chronic pain (Guo et al., 2007). Figure 1-1 










Figure 1-1 Schematic diagram of how chronic pain is transmitted. After 
receiving a pain stimulus, peripheral neurons transmit signals to the primary 
afferent neuron, causing the release of neurotransmitters and neuromodulators that 
activate the receptors on microglia and astrocytes. The glial cells are activated and 
release pro-inflammatory cytokines and other pain enhancing substances. This 
affects the presynaptic release of neurotransmitters, postsynaptic excitability, as 
well as a self-propagating mechanism of enhanced production of pain enhancing 
substances by the glial cells.  
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Astrocytic reaction is more persistent than microglial reaction after nerve 
injury, lasting more than 150 days after nerve injury. Activation of astrocytes 
results in prolongation of the pain state, and is accompanied by a reduction in 
microglial activity over time (Tanga et al., 2004). Thus, microglia are involved in 
the early development of chronic pain, while astrocytes function in sustaining the 
pain (Vallejo et al., 2010). An interesting finding was that nerve injury induces an 
increase in interleukin-18 (IL-18) and IL-18 receptors in activated microglia and 
astrocytes respectively, suggesting an interaction between microglia and 
astrocytes in the physiology of chronic pain (Miyoshi et al., 2008).  
However in some cases, astrocytes are activated without microglial 
activation, and are shown to be sufficient on their own to produce chronic pain. 
Davies et al. (2008) showed that transplantation of astrocytes derived from glial-
restricted precursor cells triggered the onset of mechanical allodynia and thermal 
hyperalgesia after spinal cord injury in rats. Hald et al. (2009) also demonstrated 
that development of hypersensitivity and activation of astrocytes occurred without 
microglial activation in chronic pain mouse models.  
 
1.1.2.1.1 T98G Cell Line as an in vitro Astrocytic Model 
The cell line used in this project is the T98G human glial cell line. T98G 
cell line is a derivative of glioblastoma and is of astrocytic origin. T98G cells 
have the transformed characteristics of immortality and anchorage independence. 
However at the same time, they act like normal human cells in that they become 
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arrested in G1 phase under stationary phase conditions of high cell density or low 
serum concentration (Stein, 1979). They have also been shown to have higher 
proliferative activity and low susceptibility to the effects of external 
environmental factors. 
The cells express glial fibrillary acidic protein (GFAP), the specific 





. Due to its biological resemblance to primary 
astrocytes, it is a widely used cell line model for the study of astrocytes (de 
Joannon et al., 2000; Gasque et al., 1996). 
 
1.1.3 Treatment Strategies for Chronic Pain and their Challenges 
Chronic pain management requires a multifaceted approach that addresses 
both the biological and psychosocial factors that contribute to and maintain the 
chronic pain. Pharmacological treatment remains the most common therapy for 
many chronic pain conditions, despite the emergence of other approaches such as 
physical therapy and cognitive behavioural therapy (Ho and Siau, 2009). 
Currently, there are no drugs that are able to control prolonged pain 
without harmful side effects. Drugs that are most commonly used for the 
treatment of chronic pain are non-steroidal anti-inflammatory drugs (NSAIDs) 
including cyclooxygenase type-2 (COX-2) inhibitors, opioids, and antidepressants 
that include tricyclic antidepressants (TCAs) and selective serotonin and 
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norepinephrine reuptake inhibitors (SSNRIs). Table 1-1 details the adverse 
effects of these drugs.  
Due to rapid advancements in disease prevention, diagnosis and 
interventions, the life span of human beings and the survival rates of patients with 
pain-inducing disorders have increased. This brings about even higher demands 
for mechanism-based treatments for chronic pain that can improve the quality of 
life. Chronic pain treatment should not be targeted solely at the general symptom, 
which is pain relief, but rather at the fundamental mechanisms that are responsible 






Table 1-1 Common pharmacological treatments for chronic pain 
 




               
 
                COX-2 inhibitors
2
 
Nausea, abdominal pain, diarrhea, dizziness, 
development of rashes 
 
 
Gastrointestinal erosion, ulceration and bleeding, 
kidney failure 
 




 Nausea/vomiting, constipation, drowsiness, 
dizziness 
 




                 










Dry mouth, dry nose, blurred vision, urinary 
retention, weight gain 
 
Nausea/vomiting, drowsiness, urinary retention 
 
 
Cardiac disease, glaucoma, suicide risk, seizures 
 
 
Hepatic dysfunction, renal insufficiency, withdrawal 




 Circulation 2005; 111: 1713-1716 
2
 JAMA 2001; 286: 954-959 
3
 Ann. Acad. Med. Singapore 2009; 38: 960-966 
4
 Pain 2007; 132: 237–251 
5
 Ann. Acad. Med. Singapore 2009; 38: 974-979
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1.1.4 Conditions related to Chronic Pain 
This study focuses on two conditions that are related to chronic pain: post-
herpetic neuralgia, an example of neuropathic pain, and osteoarthritis, an example 
of nociceptive pain. Both of these illnesses give rise to chronic, intractable pain 
that can last for months or even years, and the treatment processes are often 
difficult and slow. 
 
1.1.4.1 Post-Herpetic Neuralgia (PHN) 
 Herpes zoster is a disease due to infection by the varicella zoster virus. 
Patients with herpes zoster develop rashes confined to a specific dermatomic 
region of the skin and suffer from pain that typically resolves after four weeks. 
However, approximately 20 percent of patients experience pain even after rash 
healing, and this chronic pain syndrome, which may last for years, is known as 
post-herpetic neuralgia (PHN) (Wu et al., 2000). PHN is the most common 
complication of herpes zoster in patients who are immunocompetent or have a 
serious infection (Whitley et al., 1999). The most important risk factor for PHN is 
age; it occurs 15 times more often in patients who are more than 50 years old 
(Stankus et al., 2000). 
PHN is a type of chronic neuropathic pain that is caused by lesions to the 
peripheral nervous system. Nerves in the affected dermatomic region are damaged 
by herpes zoster and they send abnormal electrical signals to the brain. 
Nociceptors are sensitized following tissue injury, leading to hyperexcitability, 
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whereby nociceptors get activated by stimuli that would normally feel innocuous 
(peripheral sensitization). Prolonged nociceptor activation leads to enhanced 
response and abnormal state of excitability of dorsal horn neurons, enlarging the 
neuron’s receptive field to external stimuli (central sensitization) (Opstelten et al., 
2004). 
Patients with PHN usually report constant burning or stabbing pain, and 
may also suffer pain in response to non-noxious stimuli. At present, there are 
many proposed therapies targeted at PHN pain control, including antiviral agents, 
TCAs and opioid agonists, but all of them have their own side effects and very 
few treatments achieve high success rate (Dworkin et al., 2007). PHN is often 
accompanied by physical, social and occupational disabilities, hence impacting 
the quality of life of patients suffering from it. 
 
1.1.4.2 Osteoarthritis 
The most common form of arthritis, osteoarthritis is one of the main 
causes of chronic pain and long-term disability in populations over the age of 65 
worldwide. Osteoarthritis, sometimes known as degenerative arthritis, is a clinical 
syndrome involving the degradation of joints and eventual loss of cartilage and 
subchondral bone, leading to joint pain and other symptoms such as stiffness, 
tenderness and increase in intra-articular fluid (Conaghan, 2008). Knees, hips and 
hand joints are the most commonly affected sites, although any synovial joint can 
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develop osteoarthritis. Osteoarthritis is twice as prevalent in women as compared 
to men, and its incidence increases with age (Felson, 1997). 
The pathophysiology of osteoarthritis is complex, although loss of 
articular cartilage plays a main role in the disease. Physiologically, cell surface 
integrins modulate cell/extra-cellular matrix (ECM) interactions, and this is 
crucial for normal growth and homeostasis of articular cartilage. During 
osteoarthritis, uncharacteristic integrin expression leads to abnormal cell/ECM 
signaling, altering the growth and differentiation of chondrocytes, which are cells 
found in the cartilage. This is coupled with increased expression of pro-
inflammatory cytokines such as interleukin-1 (IL-1) and enzymes involved in 
ECM breakdown such as metalloproteinases, which eventually lead to the 
degradation and loss of cartilage (Iannone and Lapadula, 2003; Goldring and 
Goldring, 2006). 
The most common surgery that patients with advanced osteoarthritis of the 
knees undergo is total knee arthroplasty, or knee replacement, when other 
treatment interventions such as corticosteroids or NSAIDs have been exhausted. 
The surgery involves removing the damaged cartilage, and replacing worn 
surfaces with artificial metal and plastic bearings (Leopold, 2009). However, not 
all patients are relieved of symptoms; 8 to 23 percent of patients complain of 
prolonged residual pain or stiffness in the knee even after knee replacement 





1.2 Neurotransmitters/Neuromodulators in Chronic Pain 
Many neurotransmitters and neuromodulators are involved in the 
transmission of chronic pain. They are widely distributed throughout the CNS, co-
existing in different regions, and are involved in complex interactions that 
eventually lead to the perception of chronic pain. This section will focus on small 
molecule neurotransmitters, neuropeptides and pro-inflammatory cytokines, 
which have been well established to play important roles in chronic pain. 
 
 1.2.1 Small Molecule Neurotransmitters 
 Many small molecule transmitters, which are chemicals that are released 
by neurons for communication within the nervous system, are involved in chronic 
pain transmission. They are synthesized locally within the axon terminal. Besides 
the common small molecule neurotransmitters such as serotonin, dopamine and 
acetylcholine, there are many others that play an important role in modulating 
chronic pain. Amino acids and prostaglandins are two such examples. 
 
 1.2.1.1 Amino Acids 
 Glutamate is the main excitatory amino acid in the mammalian CNS. Its 
interaction with glutamate receptors mediates excitatory synaptic transmission in 
the CNS, hence playing an important role in both normal and pathophysiological 
nociception. Chronic pain can be maintained by a state of sensitization in the CNS, 
which is partly mediated by glutamate binding to NMDA receptors. Prolonged 
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activation of nociceptors, for example due to tissue damage or nerve injury, leads 
to a continuous release of glutamate, causing a long-lasting membrane 
depolarization that releases the voltage-dependent magnesium block of NMDA 
receptors, therefore activating them (Chizh, 2002). 
 D-serine has also been identified as a neuromodulator and co-agonist for 
NMDA receptors, and is involved in nociception, binding to the glycine site on 
the NR1 subunit of the NMDA receptor. The presence of glutamate increases the 
glycine site affinity. Intrathecal (i.t.) administration of D-serine has been 
demonstrated to be pro-nociceptive in the tail-flick assay, which is blocked by co-
administration of a selective NMDA receptor antagonist that targets the glycine 
site (Kolhekar et al., 1994). 
 Conversely, γ-amino-butyric acid (GABA) is a major inhibitory 
neurotransmitter in the brain. Neuropathic pain following peripheral nerve injury, 
which can be modeled using the chronic constriction model (CCI), is subject to 
GABAergic control. I.t. injection of GABA-A receptor antagonist bicuculline, 
when given within a few days of CCI, was demonstrated to cause a dose-
dependent increase in the magnitude of hyperalgesia (Yamamoto and Yaksh, 
1993). Furthermore, a single i.t. injection of GABA has been shown to reverse the 




 1.2.1.2 Prostaglandins 
Prostaglandins, a group of C20 fatty acids each containing a 5-carbon ring, 
are synthesized from arachidonic acid by the COX enzyme, the rate-limiting 
enzyme in the arachidonate cascade. As mentioned in Section 1.1.3, COX 
inhibitors are commonly used as a pharmacological treatment strategy for chronic 
pain. Prostaglandin E2 (PGE2) plays a major role in mediating inflammation and 
pain, and this was demonstrated when peripherally administered PGE2 produced 
hyperalgesia in mice. Anti-PGE2 monoclonal antibodies inhibited the nociceptive 
response of mice to phenylbenzoquinone (Mnich et al., 1995). The nociceptive 
response was associated with the production of prostaglandins and was blocked 
by inhibitors of prostanoid synthesis. In addition, COX inhibitors as well as 
prostaglandin receptor blockers injected subcutaneously into the affected hind 
paw produced significant relief of mechanical and thermal hyperalgesia observed 
in chronic neuropathic pain produced by partial sciatic nerve ligation in rats 
(Syriatowicz et al., 1999). This provides further evidence that PGE2 is involved in 
peripheral mechanisms underlying hyperalgesia following nerve injury. 
 
1.2.2 Neuropeptides 
Neuropeptides, another category of neurotransmitters, differ from small-
molecule neurotransmitters in both size and in the way that they are synthesized. 
Many studies involving CNS diseases and pain facilitation have focused on 
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neuropeptides, and these neuropeptides range from 3 to 36 amino acids in length 
and are synthesized in the cell body.  
 
1.2.2.1 Substance P 
Substance P belongs to the tachykinin neuropeptide family and is a key 
element in chronic pain perception. Substance P coexists with the excitatory 
amino acid glutamate in the primary afferents that respond to painful stimulation, 
and also increases glutamate activity (De Felipe et al., 1998). Substance P acting 
at its receptor neurokinin 1 (NK1) has been reported to evoke thermal 
hyperalgesia. It was demonstrated that mice carrying a disruption of the 
preprotachykinin A gene, which encodes substance P, significantly reduced 
responses to moderate to intense nociceptive pain. Pain behaviours caused by 
thermal, mechanical and chemical stimulation of somatic and visceral tissues 
were all reduced in the mutant mice (Cao et al., 1998). The role that substance P 
plays in nociception was also proven by the increase in response to noxious 
stimuli by administration of NK1 receptor agonists. Hence, it has been proposed 
that substance P receptor NK1 antagonists could be developed as analgesic drugs 
(Saravana Kumar and Gandhimathi, 2012). 
 
1.2.2.2 Nociceptin/orphanin FQ and Nocistatin 
Nociceptin/orphanin FQ (N/OFQ) and nocistatin (NST) are derived from 
the same precursor protein, prepronociceptin (ppN/OFQ), and they play important 
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roles in pain transmission and learning and memory processes in the CNS. The 
two neuropeptides play antagonizing roles in pain transmission. N/OFQ is an 
endogenous ligand for the orphan opioid-like receptor, and induces both 
hyperalgesia and allodynia when administered intrathecally in mice. NST, on the 
other hand, blocks nociceptin-induced allodynia and hyperalgesia, and also 
attenuates pain due to prostaglandins. In addition, Joseph et al. (2007) found 
increased levels of ppN/OFQ, N/OFQ and NST in the brains of rats with partial 
sciatic nerve ligation as compared to naive rats. Their spinal cords also showed a 
significant increase in ppN/OFQ level. These findings demonstrate the important 
roles of these neuropeptides in the mechanisms that give rise to chronic 
neuropathic pain. 
 
1.2.3 Pro-inflammatory Cytokines 
The role of pro-inflammatory cytokines, namely tumour necrosis factor-α 
(TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), in the initiation and 
facilitation of chronic pain has been a major field of interest in pain research. 
Physiologically, these cytokines play a role in cell proliferation, differentiation, 
gene expression and the synthesis of matrix proteins essential for cell growth and 
tissue regeneration. Most importantly, they are responsible for triggering the early 
immune response to infection by recruiting and activating immune cells at the site 
of action (Wieseler-Frank, Maier and Watkins, 2005). The first evidences of the 
role that pro-inflammatory cytokines play in pain facilitation were derived from 
studies using cytokine injections in rats. Ferreira et al. (1988) and Cunha et al. 
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(1992) found out that intraplantar injection of IL-1β and TNF-α in rats caused 
inflammatory hyperalgesia in a prostaglandin-dependent process. 
 In the spinal cord, each of these cytokines has been shown to be associated 
with the development of pain. In response to peripheral nerve injury and spinal 
nerve injury, TNF, IL-1 and/or IL-6 mRNA expression and protein levels were 
shown to be elevated in the spinal cord, enhancing pain response (Arruda et al., 
1998). The mRNA and protein expression levels of these cytokines were also 
elevated in the lumbar spinal cord of rats and mice in neuropathic pain models 
like CCI (Lee et al., 2004) and sciatic cryoneurolysis (DeLeo, Colburn and 
Rickman, 1997). Milligan et al. (2001) also found out that these cytokines, 
released into lumbar cerebrospinal fluid (CSF) from activated glia, induced 
exaggerated pain states. These cytokines have also been found to be elevated in 
the temporomandibular joint fluid of patients suffering from temporomandibular 
disorders as well as the circulating blood of patients with widespread chronic pain 
(Gur et al., 2002; Bazzichi et al., 2007).  
 Each of the main pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) 
will be elaborated on in the following subsections. 
 
1.2.3.1 Tumour Necrosis Factor-α (TNF-α) 
In the family of pro-inflammatory cytokines, TNF-α is widely considered 
the main prototype, due to its role in initiating a cascade of cytokine and growth 
factor activation. TNF-α is synthesized and released by many different cell types, 
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including Schwann cells, in response to injury or inflammation. A correlation in 
TNF-α expression level and the development of hyperalgesia or allodynia in 
chronic pain models have been demonstrated in many studies. Endoneurial 
administration of TNF-α increases the extent of chronic pain, whereas inhibition 
of TNF-α has the opposite effect (Wagner and Myers, 1996; George et al., 1999; 
Schafers et al., 2003).  
A study by Sommer and colleagues in 2001 demonstrated that preemptive 
treatment with etanercept, a recombinant TNF receptor-Fc fusion protein that 
competitively inhibits TNF-α, was able to inhibit mechanical allodynia in 
neuropathic models. This shows that TNF-α is particularly crucial in the initiation 
of neuropathic pain. Ren et al. (2011) demonstrated that the upregulation of TNF-
α in adult Sprague-Dawley rats led not only to aggravated chronic neuropathic 
pain, but also working memory deficits following peripheral nerve injury. It was 
speculated that TNF-α produced in the dorsal root ganglia (DRG) might diffuse 
into the CSF, triggering the production of more TNF-α in other brain regions 
including the hippocampus, thus leading to aggravated neuropathic pain.  
TNF-α may act by inducing the production of other cytokines and 
activating the prostanoid pathways, or directly on nociceptors. In vitro perfusion 
of TNF-α to the DRG stimulates neuronal discharges in A- and C- fibers, which 
are significantly prolonged and higher after nerve injury, showing a marked 
sensitivity of injured afferent neurons to TNF-α. Furthermore, administration of 
TNF-α into rat DRGs induces allodynia in vivo, proving its direct action on 
nociceptors (Schafers et al., 2003). 
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1.2.3.2 Interleukin-1β (IL-1β) 
 IL-1β is a potent pro-inflammatory cytokine implicated in chronic 
neuropathic pain. Its expression was shown to be elevated after nerve injury, and 
neutralizing antibodies against IL-1β receptors significantly reduced pain-related 
behaviours in neuropathic mouse models (Sommer et al, 1999). Recombinant 
human IL-1β injected in low amounts in the brain was found to induce 
hyperalgesia in rats, and this action was completely abolished by pre-treatment 
with either IL-1 receptor antagonist or sodium salicylate, a COX inhibitor. This 
suggests that the IL-1β-induced hyperalgesic behaviour is receptor-mediated and 
prostaglandin-dependent (Oka et al., 1993). In addition, IL-1β administered via 
intracerebroventricular injection was demonstrated to enhance nociceptive 
neuronal responses of the dorsal horn of the trigeminal nucleus caudalis in rats, 
and this enhancement was inhibited by pre-treatment with IL-1 receptor 
antagonist, sodium salicylate, or α-melanocyte stimulating hormone, a potent anti-
cytokine peptide (Oka et al., 1994). 
IL-1β acts via a complex signaling cascade that leads to the production of 
pronociceptive compounds from immune cells or Schwann cells, causing changes 
in gene expression and neuronal excitability. There is evidence that IL-1β also 
acts directly on nociceptive fibers or increase their responses to heat stimuli 
through an IL-1β receptor type I/tyrosine kinase/protein kinase C (PKC)-




1.2.3.3 Interleukin-6 (IL-6) 
IL-6 is one of the major neuropoietic cytokines involved in various 
neuronal functions that are important in pain maintenance. IL-6 is secreted by 
many cells, including neurons, immune cells and fibroblasts in the spinal cord and 
DRG after nerve injury in the peripheral nerves (De Jongh et al., 2003). A large 
amount of IL-6 is produced at the site of a surgical wound, and its systemic 
concentration correlates with the severity of surgery and with the extent of tissue 
injury (Holzheimer and Steinmetz, 2000).  
I.t. anti-IL-6 antibodies attenuated the hyperalgesic reaction in rat CCI 
models, thus showing the involvement of IL-6 in pain facilitation (Wieseler-Frank, 
Maier and Watkins, 2005). Oka et al. (1995) have also shown that 
intracerebroventricular injection of IL-6 stimulates thermal hyperalgesia in rats, 
and this IL-6-induced hyperalgesia is not dependent on the actions of IL-1. IL-6 
has also been found to be significantly upregulated in serum and CSF of rats 
following peripheral nerve injury (Zanjani et al., 2006). In addition, Ito et al. 
(1998) have reported that IL-6 receptor mRNA levels increased after sciatic nerve 
injury, accompanied by the increase in the expression of IL-6 signal transducing 
protein, gp130. Rats with persistent allodynia after this type of nerve injury also 
had more IL-6 expression in the DRG than rats with allodynia that had subsided. 
Clinically, IL-6 has been shown to be markedly upregulated in various 
pathologic situations associated with heightened pain and hyperalgesia. For 
instance, elevated IL-6 levels have been detected in serum of chronic neuropathic 
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pain patients. The neuronal effects of IL-6 depend on the presence of the soluble 
IL-6 receptor (sIL-6R). Evidence shows that the IL-6/sIL-6R complex acts on 
sensory neurons to increase their sensitivity to noxious stimuli through a 
gp130/Janus tyrosine kinase/PKC-dependent pathway (Sommer and Kress, 2004). 
 
 
1.3 Importance of Cerebrospinal Fluid (CSF) in Chronic Pain Research 
CSF is generated through filtration of blood in the choroid plexus, and 
through diffusion from the brain extracellular matrix into the ventricles. The clear, 
colourless fluid circulates within the subarachnoid space and ventricles of the 
brain and is in direct contact with the brain and spinal column (Zhang et al., 2005). 
CSF serves as an intracerebral transport medium for nutrients and neuroendocrine 
substances. Metabolites from various tissues in the brain are secreted into the 
interstitial space and into the CSF. 
Approximately 20% of the proteins found in the CSF are estimated to be 
derived from the brain. CSF is produced at an approximate rate of 500 mL per day, 
with a turnover of 4 times per day by drainage into the blood (Johanson et al., 
2008). This dynamically changing molecular composition of CSF reflects the 
metabolic state of the brain under healthy and diseased conditions, as well as the 
ongoing pathophysiological processes in the CNS (Wiederkehr, 1991; Seehusen et 
al., 2003). Several CSF biomarkers have been identified for various CNS diseases, 
and are used extensively in research and clinical practice. The analysis of CSF 
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remains an important diagnostic window to many other diseases affecting the 
CNS. 
 
1.3.1 Biological Markers in the CSF 
Substances in the CSF have been shown to be important biological 
markers in the treatment of chronic pain. The change in concentration of various 
proteins or peptides in the CSF is one of the most sensitive indicators of 
pathology in the CNS. The differing concentrations of various amino acids in the 
CSF have been demonstrated to be markers of chronic pain. It was shown that D-
serine levels were increased in the CSF of patients suffering from chronic knee 
pain due to osteoarthritis (Sethuraman et al., 2007). Amino acids including 
aspartate, arginine, asparagine, tyrosine and valine were also demonstrated to be 
elevated in the CSF of chronic pain patients as compared to that of acute pain 
patients. On the other hand, GABA and threonine levels were significantly lower 
(Tachibana et al., 2005).  
Neuropeptide N/OFQ levels were shown to be raised in the CSF of 
patients with chronic non-cancer pain and significantly reduced in the CSF of 
those who underwent i.t. morphine treatment for their pain (Raffaeli et al., 2006). 
Levels of CSF tau protein and β-amyloid peptide, as well as 14-3-3 protein, have 
been demonstrated to be elevated in the Alzheimer’s disease and Creutzfeldt–
Jakob Disease respectively (Holtta et al., 2012). 
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Development of PHN has been linked to increases in pro-inflammatory 
cytokine interleukin-8 (IL-8) levels in the CSF. IL-8 was demonstrated to be 
elevated in the CSF of herpes zoster patients during and at the time of rash 
healing, and the increased IL-8 concentration was shown to be highly reliable for 
predicting the development of PHN six months to one year later (Kotani et al., 
2004). Levels of major pro-nociceptive cytokines IL-6, IL-1β and TNF-α were 
shown to be elevated, while that of interleukin-10 (IL-10), an anti-inflammatory 
cytokine, were reduced in the CSF of patients suffering from chronic pain 
syndromes including Complex Regional Pain Syndrome (CRPS), diabetic painful 
neuropathy and post-traumatic neuralgia (Alexander et al., 2005; Backonja et al., 
2008). The CSF of CRPS patients also had high levels of GFAP, nitric oxide 
metabolites, glutamate and calcium. The elevation of CSF IL-6 in CRPS patients 
was shown to be greater than that of patients suffering from non-painful 
conditions like Alzheimer’s and Parkinson’s disease (Alexander et al., 2007).  
TNF-α has been documented to be upregulated in the CSF of patients 
suffering from various forms of chronic daily headache: new daily persistent 
headache, chronic migraine and post-traumatic headache. This led to the 
hypothesis that treatment-resistant chronic headache could be caused by persistent 
elevation of CSF TNF-α levels. Serum TNF-α level was not elevated in these 
patients, showing that CNS inflammation rather than systemic inflammation plays 





1.4 Aim and Scope of Study 
 Chronic pain associated with neuroinflammation and nerve injury is often 
unrelenting and difficult to treat, impacting the quality of life of an individual. A 
number of pain therapeutics such as NSAIDs and opioids have proved to be 
partially effective and may have their own side effects. Better mechanism-based 
treatments which target the underlying cellular mechanisms are required, rather 
than non-specific symptomatic treatment (Scholz and Woolf, 2002). CSF, being 
in direct contact with the ventricles of the brain and the spinal cord, contains 
substances secreted from nerve cells, reflecting changes occurring in the CNS. 
CSF analysis remains a key tool in understanding the status and functions of the 
CNS, and investigating the mechanisms of chronic pain. 
The importance of biological markers for assessing the extent of chronic 
pain or predicting effectiveness of pain therapy is well known. The changes in 
concentration of various substances in the CSF have been shown to be important 
biological markers in chronic pain treatment. To date, there are no reports on in 
vitro markers that may aid in chronic pain research. This area may be worth 
exploring due to the relative ease and convenience in measuring substances in 
vitro.  
Protein concentrations in the CSF reflect neuronal activity, which might 
be correlated with CNS disorders. The identification and characterization of 
neuropeptides or proteins in CSF that are involved in chronic pain modulation is 
important for studying the pathogenesis of this pain syndrome, and can thus 
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provide new directions for chronic pain treatment. This could lead to the 
development of potential analgesics in pain management without the adverse 
reactions or abuse tendency – major disadvantages of many chronic pain 
therapeutics used today. 
This study utilizes CSF from chronic pain patients and consists of two 
primary objectives: 
(1) To investigate pro-inflammatory cytokine release in a cell culture system 
as a potential marker for chronic pain 
Attempts would be made to analyze TNF-α, IL-1β and IL-6 release in a T98G cell 
culture system upon exposure to CSF from chronic pain patients, comparing 
between different pain groups as well as with controls. 
(2) Characterization of pain-related substances in the CSF and the signaling 
pathway involved in chronic pain 
Attempts would be made to isolate protein-like substances from CSF of chronic 
pain patients, and also to establish the signaling mechanism of chronic pain in this 








Release of Pro-inflammatory Cytokines in 
T98G Cells Upon Exposure to CSF of 
PHN Patients   
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2.1 Objectives of Chapter 
I.t. steroid therapy, using methylprednisolone acetate, once a week for four 
successive weeks, was demonstrated to alleviate PHN pain significantly (Kotani 
et al., 2000). Subsequent studies were inconclusive, with both effective and 
ineffective results (van Wijck et al., 2006; Dureja et al., 2010). This treatment 
was modified using water-soluble dexamethasone and lidocaine instead of 
methylprednisolone, and half of the patients in the study had reduced pain scores 
with this treatment while the other patients had no improvement. Pain was 
evaluated using the visual analogue scale (VAS), whereby the patient marks on a 
line from 0 mm (no pain) to 100 mm (worst imaginable pain) the point that they 
feel best represents their current state. In order to establish the effectiveness of 
steroid therapy for PHN pain, the mechanisms for differing efficacy of the steroid 
therapy among patients should be ascertained. The importance of biological 
markers in enabling the early diagnosis of pain-related diseases is well known. 
However, to date there are no established markers that can predict the efficacy of 
i.t. steroid therapy in PHN patients.  
In this chapter, the possibility that TNF-α, IL-1β and IL-6 release in an in 
vitro system could be potential markers for PHN pain, as well as for evaluating 
the effectiveness of i.t. steroid therapy in PHN patients, was examined. CSF 
samples obtained from PHN patients who had steroid therapy were added to 
T98G glioblastoma cells and the subsequent cytokine production was analyzed. 
Differences between patients in whom i.t. steroids had been effective and patients 
in whom treatment had been ineffective; as well as differences between before i.t. 
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steroid treatment and after treatment were evaluated. In addition, in vitro steroid 
effects on IL-6 release were also investigated in this T98G cell system. As the 
patients were administered with dexamethasone prior to CSF collection, attempts 
were made to determine whether there were residual steroid in the CSF which 




2.2 Materials and Methods 
2.2.1 Materials 
Human glioblastoma T98G cell line was obtained from American Type 
Culture Collection (CRL-1690; Manassas, VA, USA). ATCC-formulated Eagle’s 
Minimum Essential Medium (EMEM) and fetal bovine serum (FBS) were 
obtained from GIBCO (Grand Island, NY, USA). Phosphate buffered saline (PBS) 
was from Vivantis Technologies (Oceanside, CA, USA). Lipopolysaccharides 
(LPS) from Escherichia coli 055:B5 and 6α-methylprednisolone 21-hemisuccinate 
sodium salt were obtained from Sigma Aldrich (St Louis, MO, USA). TNF-α, IL-
1β and IL-6 enzyme-linked immunosorbent assays (ELISA) were carried out 
using DuoSet ELISA Development kits that were obtained from R&D Systems 
(Minneapolis, MN, USA). 
LiChrosorb Si 60, 5 µm, Hibar 250 × 4 mm I.D. (Merck, Darmstadt, 
Germany) analytical column was used for high performance liquid 
chromatography (HPLC). Ethyl acetate, n-hexane, dichloromethane and acetic 
acid were purchased from Merck (Darmstadt, Germany), and methanol was 
purchased from Thermo Fisher Scientific (Pittsburgh, PA, USA). DBL 





2.2.2 CSF Samples 
PHN Patients 
All PHN patients were recruited in Osaka Medical University Hospital. 
The patient population consisted of 32 Japanese PHN patients (15 males and 17 
females, with a mean age of 69 years) who had suffered from persistent pain for at 
least three months. The protocol was approved by the Research Ethics Committee 
of Osaka Medical College, and written informed consent was obtained from all 
patients. In the lateral decubitus position, a 25-gauge pencil-point spinal needle 
was inserted through the interlaminar space in the lumbar vertebrae, and 2 mL of 
CSF was obtained.   
9.9 mg (3 mL) of water-soluble dexamethasone (Banyu Merck Sharp & 
Dohme, Tokyo) and 1 mL of 1% lidocaine (AstraZeneca, Osaka, Japan), mixed 
with 1 mL of 50 % dextrose solution was injected into the lumbar i.t. space once 
per week for four weeks. Pain was evaluated just before each treatment and at the 
end of treatment. For each patient, CSF samples were collected twice, once before 
the course of treatments began (constituting the ‘before treatment’ samples) and 
another during their third treatment, prior to injection of the drugs (constituting 
the ‘after treatment’ samples). At the third i.t. steroid treatment session, the 
patients were divided into two groups: a therapy ineffective group of 17 patients 
with no change in pain score and a therapy effective group of 15 patients whose 
pain score had improved. The grouping was determined by calculating the 
“therapeutic index %”: ((pain score before treatment – pain score after treatment) 
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÷ pain score before treatment) × 100%. Patients whose therapeutic index was > 50% 
were included in the therapy effective group, while those whose index was < 50% 
were included in the therapy ineffective group.  
 
Pain-free Patients 
15 pain-free subjects (11 males and 4 females, with a mean age of 61 
years) with no history of pain and were having elective surgery (which required 
spinal anaesthesia) for conditions that are not causing pain e.g. prostatic surgery, 
were used as controls. All pain-free patients were recruited in National University 
Hospital of Singapore under approval of the DSRB of National University of 
Singapore. 
Pooled pain-free patients’ CSF was obtained by adding 100 µL of each 
CSF sample to make up 1.5 mL of pooled CSF. 
 
2.2.3 Cell Culture 
The T98G cells were cultured in 75-cm
2
 flasks containing EMEM 
supplemented with 10% FBS and maintained at 37°C in a fully-humidified 
incubator (5% CO2/95% air). Cells were passaged twice a week. Upon reaching 
80% confluence, cells were seeded onto 12-well plates and cultured overnight 
before the start of the experiment.  
The CSF was stored at -80°C immediately after collection. The CSF 
samples were thawed and aliquots were made just before the start of experiments, 
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and they were filtered through a 0.22 µm, 13 mm filter prior to use in the cell 
cultures. The EMEM in each well of the 12-well plates was aspirated and the 
wells were washed with PBS twice. CSF in two doses 50 µL and 100 μL was used 
and both doses were tested with and without the addition of 32 μg/mL LPS. LPS 
was used to enhance the release of pro-inflammatory cytokines from T98G cells. 
For all the tests, the cells were incubated in FBS-free EMEM, and CSF with or 
without LPS (total volume 1 mL), for 48 h at 37°C in a fully-humidified incubator.  
To investigate the effects of in vitro steroids, the cells were incubated with 
100 μL CSF (5 therapy effective samples and 5 therapy ineffective samples) 
collected before i.t. steroid treatment and different concentrations (0 – 12.5 μg/mL) 
of 6α-methylprednisolone 21-hemisuccinate sodium salt in FBS-free EMEM. At 
the end of 48 h, the supernatant was collected and centrifuged (3000 rpm, 5 min, 
room temperature). The top supernatant was collected and immediately analyzed 
for IL-6.  
 
2.2.4 Measurement of TNF-α, IL-1β and IL-6 Release 
TNF-α, IL-1β and IL-6 levels were determined by ELISA (DuoSet ELISA 
Development kit) according to the manufacturer’s instructions. Aliquots from 
each sample were run in duplicates. 96-well microplates pre-coated with a 
monoclonal antibody were used. After washing away unbound substances, an 
enzyme-linked polyclonal antibody was added. Following another wash step, 
substrate solution was added. Color development was stopped and color intensity 
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was measured at 450 nm using a microplate reader (Tecan Infinite M200, 
Männedorf, Switzerland). Optical densities were compared to a standard reference 
curve of increasing amounts of recombinant human TNF-α, IL-1β or IL-6 and 
quantified in pg/mL. The values were above that of the blank and fell within the 
linear range of the standard curve. The TNF-α, IL-1β and IL-6 detected in the 
control samples (cell culture without CSF added) were subtracted from the raw 
values to obtain the final values to be plotted in the figures. 
 
2.2.5 Measurement of Dexamethasone in CSF 
5 PHN (4 therapy effective and 1 therapy ineffective) patients’ CSF were 
used. 500 µL of each patient’s CSF was added to 2 mL of ethyl acetate, vortexed 
for 2 min exactly and centrifuged at 3000 rpm for 10 min at room temperature. 
The organic layer was transferred into a 2 mL Eppendorf tube and evaporated 
under a stream of nitrogen.  The residue was reconstituted in 100 µL of ethyl 
acetate.  
Shimadzu Prominence HPLC system (Kyoto, Japan) with LC20AD pump, 
SIL20A autosampler, and SPD M20A UV-visible photodiode array detector was 
used. A 17 µL aliquot of the sample was injected into the HPLC system using 
LiChrosorb Si 60, 5 µm, Hibar 250 × 4 mm I.D. analytical column. Limit of 
detection of the system was 1 µg/mL of dexamethasone. The mobile phase was n-
hexane-dichloromethane-methanol-acetic acid (266:120:26:0.8, v/v). The mobile 
phase was prepared by mixing one aliquot of mobile phase saturated with water 
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with 2 aliquots of water-free mobile phase. The flow rate was 2 mL/min and the 
eluate was monitored at UV absorbance of 242 nm (0.05 absorbance units full 
scale (AUFS)). Each sample was run in duplicates.  
A regression line of known dexamethasone concentrations (0.64 – 5.12 
µg/mL) was plotted. DBL dexamethasone sodium phosphate was added to 1 mL 
of CSF of pain-free patients and incubated at 4°C overnight for the water-soluble 
derivative to be converted to pure dexamethasone. Extraction with ethyl acetate 
and HPLC were carried out as above. Recovery tests were also performed to 
confirm that the water-soluble derivatives were converted to the active form in 
CSF. 
 
2.2.6 Statistical Analyses 
All data are expressed as mean ± standard error of mean (SEM). SPSS 
18.0 for Windows (IBM, Chicago, IL) was used for analyses. T-tests were used 
for comparisons between the therapy effective and ineffective groups and paired 
T-tests were used for comparisons within patient groups. The Mann-Whitney U 
test was used for comparing between the pain scores of before and after treatment 
groups. p values < 0.05 were considered as statistically significant. The regression 






2.3.1 TNF-α, IL-1β and IL-6 Releasing Activity in T98G Cells Upon 
Exposure to CSF of PHN Patients 
All CSF samples obtained from PHN patients (patient data in Table 2-1) 
before i.t. steroid treatment had begun, regardless of whether they were therapy 
effective or ineffective, showed IL-6 releasing activities in T98G cells. However, 
there were no TNF-α and IL-1β releasing activities seen (Figure 2-1). The levels 
of TNF-α and IL-1β were below the detection limits of the ELISA kits. IL-6 
levels were measured in the CSF samples alone and they did not contain 
detectable levels of IL-6. 
 
Table 2-1 Patient data (PHN)  












   PHN steroid therapy   
effective 
15 66.6 ± 2.3 5M 
10F 
53.8 ± 6.5 15.6 ± 2.6 
#
 70 ± 4 
   PHN steroid therapy 
ineffective 
17 70.6 ± 2.1 10M 
7F 
52.8 ± 6.0 46.1 ± 5.4
 
 13 ± 5 
 
a
 VAS: visual analogue scale, from 0 mm (no pain) to 100 mm (worst imaginable 
pain) 
b
 Therapeutic index %: ((pain score before treatment – pain score after 
treatment) ÷ pain score before treatment) × 100% 
#











Figure 2-1 TNF-α, IL-1β and IL-6 release in T98G cells upon addition of 
PHN CSF. IL-6, but no TNF-α and IL-1β, was released when T98G cells were 
treated with CSF from PHN patients who had not undergone i.t. steroid therapy. 
The CSF itself did not contain detectable levels of IL-6. 50 µL or 100 µL CSF 
was added to T98G cells on 12-well plates both in the presence and absence of 32 
μg/mL LPS, and the TNF-α, IL-1β and IL-6 levels in the cell supernatant were 
measured after 48 h by ELISA. 32 PHN patients’ CSF was analyzed for each 




2.3.2 Comparison of IL-6 Releasing Activity Between CSF of Different PHN 
Treatment Groups 
Using the Therapeutic Index %, 15 PHN patients were grouped in the 
steroid therapy effective group and 17 PHN patients were grouped in the therapy 
ineffective group. Patient data and pain scores are shown in Table 2-1. There was 
a statistically significant difference in pain scores between the before and after 
treatment groups of the therapy effective group. Conversely, the difference in pain 
scores between the before and after treatment groups of the therapy ineffective 
group was not statistically significant. 
All CSF samples obtained from PHN patients, both before and after i.t. 
steroid therapy had begun, showed IL-6 releasing activities in T98G cells, both 
with and without the presence of LPS. Figure 2-2 shows the increased release of 
IL-6 into the culture media with 100 µL of CSF compared to 50 µL of CSF in the 
absence and presence of LPS. Preliminary studies using 3 different amounts of 
CSF (25 µL, 50 µL and 100 µL) showed that IL-6 increased when the amount of 
CSF added increased, demonstrating a dose-dependent relationship (data not 
shown). 
IL-6 release was reduced when comparing CSF taken before and after i.t. 
steroid treatment, in both therapy effective and therapy ineffective groups. This 
trend was seen when both 50 µL and 100 µL of CSF were added, as well as both 





Figure 2-2 Comparisons in IL-6 release between before and after treatment 
groups, and between therapy effective and ineffective groups. IL-6 release was 
higher in the before treatment group compared to after treatment group; and in the 
therapy ineffective group compared to therapy effective group. 50 µL or 100 µL 
CSF was added to T98G cells on 12-well plates both in the (A) presence and (B) 
absence of 32 μg/mL LPS, and IL-6 levels in the cell supernatant were measured 
after 48 h by ELISA. 15 PHN therapy effective patients’ CSF and 17 PHN 
therapy ineffective patients’ CSF were analyzed. Mean ± SEM. 
 
+ p < 0.05 by 2-tailed T test, therapy effective vs therapy ineffective, using before 
treatment samples. 
* p < 0.05 by 2-tailed T test, therapy effective vs therapy ineffective, using after 
treatment samples. 
# p < 0.05 by paired T test, before treatment vs after treatment, using therapy 
effective samples. 






IL-6 releasing activity was lower when using CSF from patients in whom 
steroid therapy was subsequently effective, compared to CSF from patients in 
whom steroid therapy was ineffective, for both before and after treatment samples 
(Figure 2-2). 
 
2.3.3 Effect of in vitro Steroid on IL-6 Releasing Activity 
In the tests in which 6α-methylprednisolone 21-hemisuccinate sodium salt 
was directly added into the T98G culture medium together with before treatment 
CSF, there was a marked reduction in IL-6 release in cultures with 
methylprednisolone added compared to cultures without methylprednisolone 
added, for both steroid therapy effective and ineffective groups (Figure 2-3). 
However, IL-6 release could be completely suppressed in the therapy effective 
group (-0.71 ± 1.58 pg/mL), whereas in the therapy ineffective group, residual IL-
6 (5.07 ± 1.58 pg/mL) was still detectable in the culture media, even when a high 





Figure 2-3 IL-6 release in T98G cells upon addition of PHN CSF and 
methylprednisolone. IL-6 release from T98G cells was reduced in the presence 
of methylprednisolone for both groups. IL-6 release was completely suppressed in 
the therapy effective group, while it was incompletely suppressed in the therapy 
ineffective group. 100 µL of before treatment CSF was added to T98G cells on 
12-well plates together with 0 – 12.5 µg/mL methylprednisolone. IL-6 levels in 
the cell supernatant were measured after 48 h by ELISA. 5 therapy effective 
patients’ CSF and 5 therapy ineffective patients’ CSF were analyzed. Mean ± 
SEM, 
+
 p < 0.05 using 2-tailed T test, therapy effective vs therapy ineffective.  
 
 There was no remnant steroid detected in the PHN patients’ CSF (n=5). A 
representative chromatogram of dexamethasone standard (2.56 μg/mL) is shown 
in Figure 2-4, together with the chromatograms of 5 CSF samples (samples 2 – 5 
are therapy effective patient samples; sample 1 is a therapy ineffective patient 
sample). A regression line of known dexamethasone concentrations (0.64 – 5.12 
µg/mL) is also shown. This result confirms that there is no residual steroid in the 




















Figure 2-4 Dexamethasone analyses in CSF of PHN patients. No 
dexamethasone was detected in the CSF. The chromatogram of dexamethasone 
standard (2.56 µg/mL) is shown. Insert A shows the regression line of 
dexamethasone standards (0.64 – 5.12 µg/mL); R2 = 0.999. Mean ± SD, n = 3. 
Inserts 1 – 5 are cropped chromatograms of 5 PHN patients’ CSF samples 
analyzed at the same retention time (t = 5.8 min) and are of the same x- and y-
axes scale as that of the dexamethasone standard chromatogram. The VAS scores 
(before:after steroid treatment) of 5 PHN patients are: 1 (85:90), 2 (50:5), 3 
(35:15), 4 (50:23) and 5 (86:15).  
  























































































































































































 In this chapter, a simple in vitro method was developed to analyze the 
ability of PHN patients’ CSF to trigger pro-inflammatory cytokine release in a 
T98G cell culture system. CSF from PHN patients, both therapy effective and 
therapy ineffective, was able to stimulate IL-6 release in T98G cells, and the IL-6 
release was enhanced by the addition of LPS. LPS, being a highly immunogenic 
antigen, is a common pro-inflammatory stimuli used to activate cells to secrete 
pro-inflammatory substances in vitro. The CSF itself did not contain detectable 
IL-6 but was able to induce IL-6 release into culture media. Conversely, the other 
pro-inflammatory cytokines TNF-α and IL-1β were not detected in the T98G 
culture media. 
 TNF-α and IL-1β are known to play important roles in the transmission of 
chronic pain (Norris, Tang and Benveniste, 1994; Sommer and Kress, 2004), thus 
it was surprising that there were no TNF-α and IL-1β released from the T98G 
cells. TNF-α and IL-1β have been demonstrated to induce IL-6 expression 
physiologically (Van Wagoner et al., 1999; Palmqvist et al., 2008). One 
possibility for the lack of TNF-α and IL-1β release from T98G cells could be that 
these cytokines were degraded after downstream activation of IL-6, and hence 
they were not detected at 48 h of incubation. Since there were positive results for 
IL-6 in this cell culture system, IL-6 was used as the marker for quantification of 
chronic pain in this chapter as well as subsequent chapters. 
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 There have been many reports that state that IL-6 could be a useful 
biomarker for spinal cord injury, Sjogren’s syndrome-associated 
meningoencephalomyelitis, and CRPS (Alexander et al., 2007; Hoshina et al., 
2008; Kwon et al., 2010). This present study shows that IL-6 release in a cell 
culture may be a marker for chronic pain induced by PHN, and possibly other 
forms of chronic pain.  
Differences between the CSF of steroid therapy effective patients and 
steroid therapy ineffective patients, as well as before treatment and after treatment 
patients, were compared in terms of the amount of IL-6 released into the cell 
culture media. IL-6 release was lower when CSF collected from patients after i.t. 
steroid therapy was used to trigger the cells. This suggests that the steroid 
treatment caused certain changes in the CSF, which inhibited the IL-6 releasing 
activity caused by the CSF. The factors responsible for IL-6 release in T98G cells 
and the changes that led to inhibition of IL-6 release by the steroid treatment 
remains to be ascertained. 
 IL-6 release from T98G cells using after i.t. steroid treatment CSF were 
higher in the therapy ineffective group compared to the therapy effective group. 
Even though the pain score distributions of both groups before starting i.t. steroid 
treatment were similar (Table 2-1), IL-6 release using before treatment CSF was 
also higher in the therapy ineffective group compared to the therapy effective 
group. A simple method for detection of dexamethasone in CSF was developed 
by applying the HPLC quantification method for steroids in serum 
(Doppenschmitt et al., 1995). No dexamethasone was detected in the PHN CSF 
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samples, which might otherwise confound the findings of this study as steroid 
remnants might affect the IL-6 release. These findings suggest that there exists 
yet-to-be-identified factor(s) present in the therapy ineffective PHN patients’ CSF 
that can trigger more IL-6 release from T98G cells. The differences observed 
when using CSF taken after i.t. steroid treatment may be useful in evaluating the 
effectiveness of i.t. steroid therapy and whether the therapy should be continued. 
 Kotani et al. reported in their original study in 2000 that i.t. 
methylprednisolone was effective in the treatment of PHN pain. The in vitro IL-6 
assay developed in this study could be a useful predictive assay in evaluating the 
efficacy of i.t. steroid therapy for these patients. This is supported by the 
observation that IL-6 release was completely suppressed by high doses of in vitro 
methylprednisolone when using CSF from the therapy effective group, whereas 
this suppression was incomplete (remained at ~8% of baseline IL-6 even at high 
doses of methylprednisolone) when using CSF from the therapy ineffective group. 
The substance(s) in the CSF that cause this residual IL-6 release may be 
correlated with PHN pain and may play a part in the lack of improvement of pain 
scores of these patients. Attempts to isolate the substance(s) in the CSF that cause 
chronic pain will be discussed in Chapter 4. 
 Levels of endogenous cortisol, a steroid hormone released in response to 
stress, may affect the patients’ response to i.t. steroid treatment and also the 
release of IL-6 from T98G cells. Cortisol levels in CSF have been shown to be 
related to chronic lower back pain (Alaranta et al., 1983). It would be interesting 
as a future work, to analyze the levels of cortisol in the CSF from patients before 
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and after steroid treatment, to determine whether differences in patients’ stress 
response contribute to the effectiveness of i.t. steroid treatment. 
 In summary, an in vitro assay measuring IL-6 release from T98G glial cell 
line upon addition of CSF has been developed. This assay can act as a potential 
marker or read-out to quantify the extent of chronic pain, as well as to predict an 
individual’s response to i.t. steroid treatment. The therapy may not be effective if 
IL-6 release is not completely suppressed by steroid in this in vitro system. These 
tests may provide an objective evaluation of the efficacy of i.t. steroid therapy, 
which can also be tested prior to such treatment of PHN patients. Having 
established an in vitro assay for chronic pain, attempts were made to compare the 






Comparison of IL-6 Releasing Activity 
between CSF of Chronic Pain Patients 
and Pain-free Patients   
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3.1 Objectives of Chapter 
As CSF from PHN patients was shown to induce IL-6 release in T98G 
cells (Chapter 2), the following study was carried out to determine whether there 
was any difference in the IL-6 releasing activity between the PHN patient groups 
and a pain-free control group. CSF of patients suffering from osteoarthritis, 
another chronic pain syndrome, was also investigated to determine whether it 
could also produce the same IL-6 releasing effect.  
 The difference in IL-6 release between the chronic pain groups and pain-
free controls could reinforce the hypothesis that IL-6 could be a useful in vitro 
marker for chronic pain. In addition, if CSF from osteoarthritis patients could 
produce the same IL-6 releasing effect in T98G cells as that of PHN patients, it 
could further substantiate the usefulness of this in vitro system, and the 
mechanisms involved that lead to chronic pain brought about by these syndromes 
could be further understood. Attempts were also made to use primary astrocytes 
in place of T98G cell line to determine whether primary culture has the same IL-6 
releasing activity as the cell line. 
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3.2 Materials and Methods 
3.2.1 Materials 
Earle's Balanced Salt Solution (EBSS) was purchased from Sigma Aldrich 
(St Louis, MO, USA). Dulbecco's Modified Eagle Medium (DMEM) was 
obtained from GIBCO (Grand Island, NY, USA). The Papain Dissociation 
System (Papain Vial, DNase Vial and Inhibitor Vial) was obtained from 
Worthington Biochemical Corporation (Lakewood, NJ, USA). 
Formaldehyde, mouse anti-GFAP antibody and 4',6-diamidino-2-
phenylindole (DAPI) was obtained from Sigma Aldrich (St Louis, MO, USA). 
Triton X-100 was purchased from Bio-Rad (Hercules, CA, USA) and secondary 
fluorescence-conjugated antibody Alexa Fluor 488 was from Invitrogen (Carlsbad, 
CA, USA). Fluorescence aqueous mounting medium was purchased from Dako 
(Glostrup, Denmark). 
 
3.2.2 CSF Samples 
PHN Patients 
Details of CSF collection from PHN patients are described in Chapter 2 
(Section 2.2.2, Page 32). The patients were divided into steroid therapy effective 






All osteoarthritis patients were recruited in National University Hospital 
of Singapore under approval of the Domain Specific Review Board (DSRB) of 
National University of Singapore. The patient population consisted of 15 patients 
with osteoarthritis (7 males and 8 females, with a mean age of 67 years). After 
obtaining written informed consent, CSF was collected during subarachnoid 
puncture, from patients with moderate to severe degenerative osteoarthritis 
affecting the knees who were to undergo joint replacement surgery under spinal 
anaesthetic technique. CSF was extracted by inserting a spinal needle into the 
subarachnoid space of the lumbar vertebrae, and 1–2 mL of CSF was withdrawn. 
 
Pain-free Patients 
Details of CSF collection from pain-free patients are described in Chapter 
2 (Section 2.2.2, Page 33). 
 
3.2.3 Culture of Primary Astrocytes 
The primary astrocytes were a generous gift from Ms Jeyapriya Raja 
Sundaram of Department of Pharmacology (National University of Singapore). 
Briefly, the brains of newborn (postnatal day 1–2 old) mice were removed and 
meninges-free cortices were cut into small pieces and digested using the Papain 
Dissociation System. The cortices were re-suspended in Papain Solution. The 
mixture was triturated 10 times and incubated for 40 min at 37°C, with shaking 
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every 10 min. After another round of trituration, the mixture was centrifuged at 
1000 rpm for 5 min at 4°C. The supernatant was removed, and Stop Solution was 
added to the pellet. After triturating 3 times, the mixture was incubated at room 
temperature for 10 min, and next centrifuged at 800 rpm for 10 min at 4°C. The 
supernatant was removed and the pellet was transferred to DMEM supplemented 
with 10% FBS, 2 mM penicillin-streptomycin-glutamine and 10 mM sodium 





To ensure the purity of the primary culture, immunocytochemistry was 
carried out to identify astrocytes in the culture. Glial cells were seeded on 
coverslips and fixed with 4 % formaldehyde for 20 min. After washing with PBS, 
the cells were permeabilized with 0.1% Triton X-100 for 20 min. After another 
washing step, the cells were blocked with 5% FBS for 30 min, then incubated 
with mouse anti-GFAP antibody (1:1000) in 5% FBS for 1 h at room temperature. 
The cells were washed 3 times with PBS, then incubated with secondary antibody 
Alexa Fluor 488 (1:200) in 5% FBS for 1 h at room temperature. The nuclei were 
counterstained with DAPI. The coverslips were washed with PBS and mounted on 
glass slides in fluorescence aqueous mounting medium. Fluorescent confocal 




3.2.5 Measurement of IL-6 in T98G and Primary Astrocyte Cell Culture 
The method for measuring IL-6 in T98G cell culture is as described in 
Chapter 2 (Section 2.2.3 and 2.2.4, Page 33). T98G cells seeded onto 12-well 
plates were incubated with CSF from 1) PHN therapy effective, PHN therapy 
ineffective and pain-free patients; and 2) osteoarthritis patients and pain-free 
patients, at two doses 50 µL and 100 µL, with and without the addition of 32 
μg/mL LPS (total volume 1 mL). After 48 h at 37°C in a fully-humidified 
incubator, the supernatant was collected and analyzed for IL-6 using ELISA. 
 Similarly, primary astrocytes were seeded onto 12-well plates and 
incubated with CSF from PHN patients at 50 µL and 100 µL, with and without 
the addition of 32 μg/mL LPS. The supernatant was similarly collected and 
analyzed for IL-6 using ELISA after 48 h incubation at 37°C.  
 The IL-6 detected in the control samples (cell culture without CSF added) 
was subtracted from the raw values to obtain the final values to be plotted in the 
figures. 
 
3.2.6 Statistical Analyses 
All data are expressed as mean ± SEM. SPSS 18.0 for Windows (IBM, 
Chicago, IL) was used. T-tests were used for comparisons between PHN therapy 
effective, PHN therapy ineffective and control groups; and between osteoarthritis 




3.3.1 Comparison between PHN Therapy Effective, Therapy Ineffective and 
Control Group 
The patients’ data are shown in Table 3-1. IL-6 release from T98G cells 
upon addition of PHN CSF samples was compared with that of pain-free control 
samples. The PHN samples used were CSF that was collected before the course of 
i.t. steroid treatment. IL-6 release upon exposure to CSF of PHN therapy effective 
patients was not significantly different from that of pain-free controls, for both 50 
µL and 100 µL of CSF and both with and without addition of LPS (Figure 3-1). 
CSF from PHN therapy ineffective patients, on the other hand, triggered more IL-
6 than the control group. The difference in IL-6 release between PHN therapy 
ineffective and control group was significant when 100 µL of CSF was added in 
the absence of LPS. 
 
Table 3-1 Patient data (Control, PHN and osteoarthritis) 
Group  n Age Gender 
Control 15 61.7 ± 2.9 11M 
4F 
 
PHN steroid therapy effective 15 66.6 ± 2.3 5M 
10F 
 
PHN steroid therapy ineffective  17 70.6 ± 2.1 10M 
7F 
 




























Figure 3-1 Comparisons in IL-6 release between control, PHN therapy 
effective and PHN therapy ineffective groups. IL-6 release was higher in the 
PHN therapy ineffective group compared to control group; whereas there was no 
significant difference between PHN therapy effective group and control group. 50 
µL or 100 µL CSF was added to T98G cells on 12-well plates both in the 
presence and absence of 32 μg/mL LPS, and IL-6 levels in the cell supernatant 
were measured after 48 h by ELISA. 15 control patients’ CSF, 15 PHN therapy 
effective patients’ CSF and 17 PHN therapy ineffective patients’ CSF were 
analyzed. The CSF from PHN patients were those that were collected before i.t. 
steroid treatment. Mean ± SEM, 
+
 p < 0.05 using 2-tailed T test, PHN therapy 
effective vs PHN therapy ineffective; * p < 0.05 using 2-tailed T test, control vs 
PHN therapy ineffective. 
 
  




























(+) LPS (-) LPS 
+ 































3.3.2 Comparison between Osteoarthritis and Control Group  
Osteoarthritis and pain-free patients data are shown in Table 3-1. IL-6 
release when CSF of osteoarthritis patients were added to the cells was 
significantly higher than that when CSF of pain-free controls were added (Figure 
3-2). This trend could be seen when both 50 µL and 100 µL of CSF was used, 






















Figure 3-2 Comparison in IL-6 release between control and osteoarthritis 
groups. IL-6 release was higher in the osteoarthritis group compared to control 
group. The CSF itself did not contain detectable levels of IL-6. 50 µL or 100 µL 
CSF was added to T98G cells on 12-well plates both in the presence and absence 
of 32 μg/mL LPS, and IL-6 levels in the cell supernatant were measured after 48 h 
by ELISA. 15 control patients’ CSF and 15 osteoarthritis patients’ CSF were 
analyzed. Mean ± SEM, 
+
 p < 0.05 using 2-tailed T test, control vs osteoarthritis.  
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3.3.3 IL-6 Release from Primary Astrocytes Upon Exposure to CSF of 
Chronic Pain Patients 
Immunocytochemistry was carried out to ensure the purity of the primary 
astrocytic culture. The cultures were found to be 90% pure, containing mostly 
astrocytes, based on visualization of the fluorescence staining of astrocyte-
specific GFAP superimposed onto DAPI-stained cell nuclei (Figure 3-3). CSF of 
PHN patients (both therapy effective and ineffective) were added to the primary 
astrocytes in place of T98G cells, and IL-6 release was measured. There was no 
IL-6 release from the astrocytes when exposed to CSF, both before steroid 




Figure 3-3 Immunocytochemical analysis of primary astrocytes. Cultures 
were fixed and immunostained with anti-GFAP antibody (green) and DAPI (blue). 









Figure 3-4 IL-6 release in primary astrocytes upon addition of PHN CSF. No 
IL-6 was released when PHN CSF was added to primary astrocytes. 50 µL or 100 
µL CSF was added to primary astrocytes on 12-well plates both in the presence 
and absence of 32 μg/mL LPS, and IL-6 levels in the cell supernatant were 
measured after 48 h by ELISA. 3 PHN therapy effective patients’ CSF and 3 PHN 




 In order to establish IL-6 as a potential in vitro biological marker for 
chronic pain, comparisons have to be made between the IL-6 levels triggered by 
CSF of chronic pain patients and that of pain-free controls. Using the same in 
vitro method developed in Chapter 2, differences in the IL-6 releasing activities of 
CSF of PHN therapy effective, therapy ineffective and controls were ascertained. 
Patients from the two groups were approximately of the same age group (Table 3-
1), which eliminates the possibility that age may play a role in the differences in 
IL-6 release.  
IL-6 release when cells were treated with PHN therapy ineffective patients’ 
CSF was significantly higher than that when cells were treated with control CSF. 
Therapy effective patients’ CSF, on the other hand, triggered IL-6 release 
amounts that were not significantly different from that of control CSF. This result 
is interesting as it showed that despite both groups being CSF from PHN patients, 
CSF from patients that that did not respond well to steroid treatment contained 
substance(s) that were able to trigger IL-6 release, which was otherwise not found 
in CSF from those that responded well to treatment. These substances were 
present in the CSF even before the course of i.t. steroid treatment began, 
rendering the patients non-responsive to the subsequent steroid therapy. A study 
by Lu et al. in 2012 demonstrated a decrease in 9 proteins, including lipocalin-
type prostaglandin D synthase (L-PGDS), and an increase in 5 proteins, in the 
CSF of PHN patients after i.t. steroid therapy, for short term PHN pain. L-PGDS 
catalyzes the production of prostaglandins, which are involved in nociception. 
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Steroid therapy had no effect on long-term PHN pain, however, and the authors 
suggested that factors other than L-PGDS were responsible for that. Thus the 
present study further substantiates these findings that the CSF contains presently 
unknown factor(s) that contribute to chronic pain and lead to the ineffectiveness 
of steroid therapy for these patients. 
 The effectiveness of the in vitro IL-6 assay system in quantifying the 
degree of chronic pain was investigated further by analyzing the CSF of patients 
of another chronic pain condition: osteoarthritic pain. As highlighted in Chapter 1, 
osteoarthritis is a well-known problematic cause of chronic pain in populations 
around the world. Despite it not being a life-threatening disease, the morbidity 
associated with osteoarthritis is significant; WHO approximates that 80% of 
patients have limitations of movement, and 25% have difficulties performing 
daily activities. 
The average ages of both osteoarthritis and control groups were similar 
(Table 3-1). The CSF itself was checked for presence of IL-6 using ELISA and 
no IL-6 could be detected. Osteoarthritis patients’ CSF triggered significantly 
more IL-6 release than control patients’ CSF. Lindh et al. (1997) found that CSF 
levels of substance P-like immunoreactivity were elevated in osteoarthritis 
patients as compared to that of healthy volunteers, and the levels were positively 
correlated to the degree of pain. The present study once again suggests that there 
exists certain substance(s) in the CSF of osteoarthritis patients that can trigger 
much more IL-6 release in T98G cells, which is correlated with the magnitude of 
chronic pain, and are otherwise not found in CSF of patients that do not 
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experience pain. Proteomic and peptidome analysis of CSF have yielded the 
detection of several hundred proteins or peptides that may be valuable as 
biomarkers in various diseases related to the nervous system (Zhang et al., 2005; 
Holtta et al., 2012). Many biological markers in CSF that are associated with 
chronic pain have also been established. The current study introduces the 
possibility of another biological marker in CSF of chronic pain patients that can 
trigger IL-6 release in T98G cells.  
 In addition, attempts were made to investigate whether the IL-6 release by 
T98G cells could be replicated in primary astrocytes, hence enhancing the 
physiological relevance of the study. Unfortunately, no IL-6 release was observed 
in primary astrocytes when treated with CSF of chronic pain patients. As the 
primary astrocytes were derived from mice, the species difference (human CSF 
and mice astrocytes) might have contributed to the negative results. However, the 
effectiveness of this T98G cell culture system as a means of analyzing and 
determining the extent of chronic pain cannot be ignored. Hence it can be 
concluded that the measurement of IL-6 release from T98G glial cell line acts 
uniquely as a valuable analytical tool and read-out for the quantification of 
chronic pain, providing an objective and unbiased assessment of the extent of 
chronic pain, as opposed to subjective assessments such as pain score ratings of 
patients. Utilizing this in vitro T98G cell assay, purification and characterization 
of the substance(s) in the CSF of chronic pain patients that lead to IL-6 release 
were carried out in the next chapter. Due to similar IL-6 releasing activities of the 
CSF samples from both chronic pain syndromes, and the difficulty in obtaining 
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more PHN CSF samples, isolation of substance(s) in the following chapter were 











Purification of Protein-like Compounds 
from CSF of Chronic Pain Patients   
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4.1 Objectives of Chapter 
Proteinous substances or compounds play a dominant role in various 
biological processes. They form a large part of the protein turnover in the form of 
degradation products or processed forms of larger proteins (Heine et al., 2002). 
Many pathological processes like CNS diseases are reflected by distinctive 
alterations in the CSF contents. Protein or peptide concentrations in the CSF 
hence reflect these processes and can be correlated to CNS disorders. 
 Having established an in vitro assay system in the previous chapters, and 
proven that CSF of chronic pain patients triggers IL-6 release in T98G cells, 
attempts were made to use this assay system in the separation and purification of 
substance(s) in the CSF that lead to chronic pain. Multiple column 
chromatography steps were applied to CSF of chronic osteoarthritic pain patients, 
separating the CSF into different fractions and using these fractions to trigger 
T98G cell cultures to release IL-6. The CSF fractions that could trigger IL-6 
release would contain pain-enhancing substances that contribute to chronic pain in 
these patients.  
 The effects of lignocaine and albumin, two possible confounding factors 






4.2 Materials and Methods 
4.2.1 Materials 
10 kDa molecular weight cut-off amicon centrifugal filter device was 
purchased from Millipore (Billerica, MA, USA). Pronase (5.5 U/mg; protease 
from Streptomyces griseus) was from Sigma Aldrich (St Louis, MO, USA). 
Sodium phosphate buffer was prepared using sodium dihydrogen phosphate and 
disodium hydrogen phosphate (Merck, Darmstadt, Germany). 
 All chemicals and solvents used for HPLC were of HPLC grade. 
Acetonitrile was obtained from RCI Labscan (Bangkok, Thailand). Methanol and 
trifluoroacetic acid (TFA) were from Thermo Fisher Scientific (Pittsburgh, PA, 
USA). Hydrochloric acid was from Merck (Darmstadt, Germany). The Jupiter 
C18, 5 µm, 250 × 4.6 mm HPLC column and Luna C8, 5 µm, 250 × 4.6 mm 
HPLC column were obtained from Phenomenex (Torrance, CA, USA). 
 Lignocaine (lidocaine hydrochloride injection) was obtained from Hospira 
(Lake Forest, IL, USA). Albumin from human serum was obtained from Sigma 
Aldrich (St Louis, MO, USA). 
 
4.2.2 CSF Samples 
1–2 mL of CSF was collected from pain-free controls and osteoarthritis 
patients as described in Chapter 2 (Section 2.2.2, Page 33) and Chapter 3 (Section 
3.2.2, Page 51). Since neuropeptide/protein concentration in CSF is reported to be 
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in femtomole range, it was required to pool samples from a few patients. 10 mL 
of CSF was obtained for each of the two groups by pooling several samples 
together. All CSF samples were kept in -80°C immediately after collection and 
pooled just before the start of the purification process.  
 
4.2.3 Preliminary Experiments on CSF  
4.2.3.1 Separation of CSF by Molecular Weight  
500 µL of pooled osteoarthritis CSF was added into the reservoir of a 10 
kDa molecular weight cut-off amicon centrifugal filter device, and centrifuged at 
10 000 rpm for 95 min at 4°C. The filtrate constituted the CSF fraction that was 
<10 kDa molecular weight. 500 µL of PBS was added into the reservoir and 
centrifuged at 10 000 rpm for 35 min at 4°C. After repeating this washing step 
twice, 250 µL of EMEM was added into the reservoir and inverted into a 
collection tube after shaking for 30 sec. The tube was centrifuged at 1000 g for 3 
min at 4°C. This was repeated again and the filtrate was collected as CSF fraction 
that is >10 kDa molecular weight. 
 
4.2.3.2 Treatment of CSF with Pronase 
500 µL of pooled osteoarthritis CSF was incubated with either 0.01 U 
pronase dissolved in 100 µL of 0.1M sodium phosphate buffer (pH 7.5) or PBS at 
room temperature overnight. This was followed by incubation at 100°C for 10 
min, before the start of cell culture experiments.  
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4.2.3.3 Measurement of IL-6 in T98G Cell Culture 
The method for measuring IL-6 in T98G cell culture is the same as that 
described in Chapter 2 (Section 2.2.3 and 2.2.4, Page 33). To determine the CSF 
fraction that triggers IL-6 release from T98G cells, the cells were seeded onto 24-
well plates and incubated with 1) CSF <10 kDa molecular weight fraction, 2) 
CSF >10 kDa molecular weight fraction, and 3) original pooled CSF, at two doses 
25 µL and 50 µL, with and without the addition of 32 μg/mL LPS (total volume 
500 mL). To determine whether pronase inactivates the IL-6 releasing activity, 
the cells were incubated with 1) pronase-treated CSF, 2) PBS-treated CSF, and 3) 
original pooled CSF, at two doses 25 µL and 50 µL, with and without the addition 
of 32 μg/mL LPS (total volume 500 mL). After 48 h at 37°C in a fully-humidified 
incubator, the supernatant was collected and analyzed for IL-6 using ELISA. The 
IL-6 detected in the control samples (cell culture without CSF added) was 
subtracted from the raw values to obtain the final values to be plotted in the 
figures. 
 
4.2.4 Separation of CSF into Different Fractions 
A new approach based on multiple chromatography steps was developed 
for purification of peptides in CSF of chronic pain patients. The overall 





4.2.4.1 CSF Fractionation using HPLC 
The CSF purification procedure was carried out using a Shimadzu HPLC 
system (Kyoto, Japan) with LC10ADVP pump, SPD10AVP UV-Visible detector 
and SCL 10AVP system controller and using Class-VP (version 5.03) software for 
system control and peak analysis. 
 1 mL pooled osteoarthritis CSF was diluted with 1 mL 0.1% TFA and the 
pH was adjusted to below 3.0 with 1N hydrochloric acid. The sample was loaded 
on a Jupiter C18, 5 µm, 250 × 4.6 mm column. The solvent system consisted of 
10% acetonitrile, 0.1% TFA in water (buffer A) and 80% acetonitrile, 0.1% TFA 
in water (buffer B). Elution was carried out at a flow rate of 1 mL/min and 
absorbance monitored at 214 nm. After sample injection, 100% buffer A was used 
for elution for 15 min till a stable baseline was established, followed by a linear 
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gradient from 10% to 80% buffer B over 45 min. Fractions corresponding to 
various peaks were collected manually and lyophilized individually. These 
fractions were then individually tested for IL-6 release in T98G cell culture. 
CSF fractions that triggered IL-6 release in the T98G cells were pooled 
and lyophilized, and reconstituted with 1 mL 10% acetonitrile-0.1% TFA in water. 
The sample was loaded on a Luna C8, 5 µm, 250 × 4.6 mm column. The solvent 
system once again consisted of 10% acetonitrile, 0.1% TFA in water (buffer A) 
and 80% acetonitrile, 0.1% TFA in water (buffer B). Elution was performed at a 
flow rate of 1 mL/min and absorbance monitored at 214 nm. 100% buffer A was 
used for elution for 15 min after sample injection till the baseline stabilized, 
followed by a 45 min linear gradient from 10% to 80% buffer B. Fractions 
corresponding to various peaks were collected manually and lyophilized 
individually. They were then individually tested for IL-6 release in T98G cell 
culture. 
1 mL pooled pain-free control CSF, after dilution with 1 mL 0.1% TFA 
and the pH adjusted to below 3.0 with 1N hydrochloric acid, was similarly 








4.2.4.2 Measurement of IL-6 in T98G Cell Culture 
The lyophilized fractions obtained from HPLC were reconstituted with 1 
mL EMEM. T98G cells seeded on 24-well plates were incubated with the 
different fractions at two doses 25 µL and 50 µL, with and without the addition of 
32 μg/mL LPS (total volume 500 mL) for 48 h at 37°C in a fully-humidified 
incubator. The supernatant was then collected and analyzed for IL-6 using ELISA 
as described in Chapter 2. The IL-6 detected in the control samples (cell culture 
without CSF fractions added) was subtracted from the raw values to obtain the 
final values to be plotted in the figures. 
 
4.2.5 IL-6 Release from T98G Cells When Exposed to Lignocaine and 
Albumin 
Different concentrations of lignocaine (0 – 5 mg/mL) were added to T98G 
cells directly in 24-well plates and incubated for 48 h at 37°C in a fully-
humidified incubator. The supernatant was then collected and analyzed for IL-6 
using ELISA as described in Chapter 2. The IL-6 detected in the control samples 
(cell culture without lignocaine added) was subtracted from the raw values to 
obtain the final values to be plotted in the figures.  
Similarly, different concentrations of albumin (0 – 10 mg/mL) were added 





4.2.5 Statistical Analyses 
All data are expressed as mean ± SEM. SPSS 18.0 for Windows (IBM, 
Chicago, IL) was used for analyses. T-tests were used for comparisons between 
IL-6 releasing activities of CSF fractions < 10K MW and > 10K MW; as well as 
between IL-6 releasing activities of CSF pre-treated with PBS and CSF pre-






4.3.1 CSF Fraction >10 kDa Molecular Weight Triggered IL-6 Release in 
T98G Cells 
Pooled osteoarthritis CSF was separated into two fractions: one fraction 
consisting of compounds less than 10 kDa molecular weight; and one fraction 
consisting of compounds more than 10 kDa molecular weight. IL-6 release was 
observed in T98G cells exposed to 25 µL and 50 µL of the CSF fraction > 10 kDa 
molecular weight, both in the presence and absence of LPS. Conversely, no IL-6 
release was seen in T98G cells exposed to CSF fraction < 10 kDa molecular 






























Figure 4-1 IL-6 release in T98G cells upon addition of pooled osteoarthritis 
CSF of < 10 kDa molecular weight CSF and pooled osteoarthritis CSF of > 10 
kDa molecular weight. IL-6 was released when > 10 kDa molecular weight CSF 
was added to T98G cells, but not when < 10 kDa molecular weight CSF was 
added. 25 µL or 50 µL CSF was added to T98G cells on 24-well plates both in the 
presence and absence of 32 μg/mL LPS, and IL-6 levels in the cell supernatant 
were measured after 48 h by ELISA. Data are the mean ± SEM of 3 independent 
experiments. 
+
 p < 0.05 using 2-tailed T test, < 10 kDa MW vs > 10 kDa MW.  
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4.3.2 Pronase Attenuated IL-6 Release in T98G Cells 
IL-6 release was observed in T98G cells upon exposure to pooled 
osteoarthritis CSF pre-treated with PBS as a control. On the other hand, pooled 
osteoarthritis CSF pre-treated with pronase, a mixture of proteases isolated from 
the extracellular fluid of Streptomyces griseus, was unable to trigger IL-6 release 
in T98G cells (Figure 4-2). 
 
Figure 4-2 IL-6 release in T98G cells upon addition of pooled osteoarthritis 
CSF pre-treated with pronase. No IL-6 was released when CSF pre-treated with 
pronase was added to T98G cells. 25 µL or 50 µL CSF, pre-treated with either 
PBS or pronase, was added to T98G cells on 24-well plates both in the presence 
and absence of 32 μg/mL LPS, and IL-6 levels in the cell supernatant were 
measured after 48 h by ELISA. Data are the mean ± SEM of 3 independent 
experiments. 
+




4.3.3 Separation of CSF by HPLC 
4.3.3.1 HPLC on Pooled CSF 
Pooled osteoarthritis CSF was subjected to HPLC separation, and the 
chromatogram is shown in Figure 4-3A. Two separate runs were carried out, to 
ensure that the peaks obtained were consistent. The fractionated peaks 
corresponding to the letters A – O were collected separately.  
  





Detector A Ch1:214nm 
 

























































Figure 4-3 HPLC of pooled osteoarthritis CSF and IL-6 releasing activity of 
the peaks. (A) Chromatogram obtained from HPLC of pooled osteoarthritis CSF. 
1 mL pooled osteoarthritis CSF (diluted with 1 mL 0.1% TFA; pH < 3.0) was 
subjected to HPLC (Jupiter C18, 5 µm, 250 × 4.6 mm column). Peaks A – O were 
collected separately, lyophilized and reconstituted with EMEM. 25 µL or 50 µL 
of each peak, with and without the addition of 32 μg/mL LPS, was used to trigger 
T98G cells on 24-well plates. The peaks labeled in red were able to trigger IL-6 
release in T98G cells. (B) IL-6 release in T98G cells upon addition of peaks C, J, 
K, L and O. Data are the mean ± SEM of 2 independent experiments.  
(B)  
Pooled Osteoarthritis CSF 




































































































































































































 After lyophilization and reconstitution with EMEM, each peak was used 
to trigger T98G cells and the IL-6 release was measured. Peaks that are labeled in 
red in Figure 4-3A (Peaks C, J, K, L and O) were able to trigger IL-6 release in 
T98G cells, and the IL-6 release triggered by each peak was approximately 75% 
of the IL-6 release triggered by original pooled osteoarthritis CSF (Figure 4-3B). 
 
4.3.3.2 HPLC on Pooled Active Fractions 
The peaks that could trigger IL-6 release were pooled, lyophilized, and 
reconstituted with 1 mL 10% acetonitrile-0.1% TFA in water, then subjected to 
HPLC separation. The chromatogram obtained is shown in Figure 4-4A. The 
peaks A1 – M1 were collected separately. 
 Each peak was then used to trigger T98G cells and the IL-6 release was 
measured. The peaks that are labeled in red in Figure 4-4A triggered the cells to 
release IL-6. Each peak could trigger approximately 60% of the total IL-6 release 


























































































Figure 4-4 HPLC of pooled active fractions from previous HPLC run, and 
IL-6 releasing activity of the peaks. (A) Chromatogram obtained from HPLC of 
pooled active fractions from the previous HPLC run. The peaks from the previous 
run that could trigger IL-6 release were pooled, lyophilized and reconstituted with 
1 mL 10% acetonitrile-0.1% TFA in water and subjected to HPLC (Luna C8, 5 
µm, 250 × 4.6 mm column). Peaks A1 – M1 were collected separately, 
lyophilized and reconstituted with EMEM. 25 µL or 50 µL of each peak, with and 
without the addition of 32 μg/mL LPS, was used to trigger T98G cells on 24-well 
plates. The peaks labeled in red were able to trigger IL-6 release in T98G cells. (B) 
IL-6 release in T98G cells upon addition of peaks I1, J1 and L1. Data are the 
mean ± SEM of 2 independent experiments.  




















































































Pooled Osteoarthritis CSF 

























































4.3.4 Comparison between Chromatograms Obtained from HPLC of 
Osteoarthritis CSF and Control CSF  
Pooled osteoarthritic pain CSF and pooled pain-free control CSF was 
subjected to HPLC separation using the same HPLC column and linear gradient 
as the first HPLC separation of osteoarthritic pain CSF (Section 4.3.3.1). 
















Figure 4-5 Chromatograms obtained from HPLC of (A) pooled osteoarthritis 
CSF and (B) pooled pain-free control CSF. 1 mL pooled CSF (diluted with 1 
mL 0.1% TFA; pH < 3.0) was subjected to HPLC (Jupiter C18, 5 µm, 250 × 4.6 
mm column). The differences in the two chromatograms are shown in the boxes. 
  





Detector A Ch1:214nm 
  





Detector A Ch1:214nm 
  
(A) CSF of chronic osteoarthritic pain patients 
(B) CSF of pain-free patients 
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4.3.5 Effects of Lignocaine and Albumin on IL-6 Release 
Addition of different concentrations of lignocaine, a local anaesthethic 
drug administered subcutaneously to the patients, directly to the T98G cell culture 
did not lead to IL-6 release (Figure 4-6). 
 Low concentrations of albumin added directly to the T98G cell culture did 
not trigger IL-6 release. However at high concentrations of 1 and 10 mg/mL, IL-6 
was released (Figure 4-7). 
 
 
Figure 4-6 IL-6 release in T98G cells upon addition of lignocaine. No IL-6 
was released when lignocaine was added to T98G cells. 0 – 5 mg/mL of 
lignocaine was added to T98G cells, and IL-6 levels in the cell supernatant were 















































Figure 4-7 IL-6 release in T98G cells upon addition of albumin. IL-6 was 
released only when high concentrations of albumin were added to T98G cells. 0 – 
10 mg/mL of albumin was added to T98G cells, and IL-6 levels in the cell 
supernatant were measured after 48 h by ELISA. Data are the mean ± SEM of 3 















































 A strategy that is different from proteomics was developed for purification 
of protein-like substances from the CSF of chronic pain patients. Steps were taken 
before the actual HPLC purification to confirm that the IL-6 releasing activity in 
T98G cells were caused by substances that were protein in nature. The 
preliminary study using ultra-centrifugation showed that the fraction of CSF that 
triggered IL-6 releasing activity was more than 10K in molecular weight. Pronase 





-leucine aminopeptidases, and one Zn
2+
 
carboxypeptidase, and is capable of digesting both denatured and native proteins 
into individual amino acids (Walker and Sweeney, 2002). Treatment of CSF with 
pronase attenuated the IL-6 releasing activity in T98G cells, thus confirming that 
the substance that causes IL-6 release has a protein moiety. 
 The technique of radioimmunoassay (RIA) has been a common method to 
study protein or peptide concentrations in CSF. However it has the disadvantage 
of cross-reactivity of peptides that have similar structures with the antibodies. The 
presence of proteins and salts in biological samples like CSF may also interfere 
with the RIA process (Liu et al., 2000). 2-dimensional gel electrophoresis, a 
popular method for protein analysis, also has its shortcomings in small peptide or 
protein analysis, as low-molecular weight protein mixtures cannot be resolved. 
The recovery of proteins from 2-dimensional gels is also often a problem (Schulz-
Knappe et al., 2001). HPLC has the advantage in that the protein-like compounds 
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in the CSF remain in liquid phase throughout all the processing steps and are in 
unaltered molecular forms, hence improving the recovery. 
In this study, multiple column chromatography techniques using reverse 
phase HPLC was applied. The peaks and fractions obtained from each HPLC 
procedure were all individually screened for IL-6 releasing activity in T98G cells, 
using the in vitro system established in Chapters 2 and 3. Individual peaks 
obtained from HPLC of pooled osteoarthritis patients’ CSF that could trigger IL-6 
release in T98G cells were combined together and subjected to a more stringent 
HPLC run using a column with a smaller particle size compared to the first HPLC 
run, hence providing an increased surface area and a better separation than the 
first. The individual peaks obtained were tested for their ability to trigger IL-6 
release in T98G cells, and 3 of these peaks were singled out (Figure 4-4). 
 Proteome and peptidome analysis of CSF has only been carried out in 
recent years, offering insights into the composition of CSF as well as 
complementing the constant search for biomarkers of CNS disorders. The 
technique of mass spectrometry has advanced rapidly to not only enable detection 
of large numbers of proteins in CSF, but also identification of endogenously 
modified proteins and peptides. The protein population of CSF is mostly 
contributed by protein secretion coupled with proteolytic processes such as cell 
surface remodeling, protein shedding and formation of regulatory peptides. Mass 
spectrometry can be used to study these processing events and the protein 
modifications in the CSF, correlating them to specific pathophysiological events 
(Zougman et al., 2007; Holtta et al., 2012). 
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 In this chapter, different fractions of CSF of chronic pain patients, from 
both preparative and analytical HPLC runs, that were able to trigger IL-6 release 
in T98G cells have been isolated. These fractions have been manually collected 
and will be subjected to matrix-assisted laser desorption/ionization (MALDI) 
time-of-flight (TOF) mass spectrometry to determine the molecular weight of the 
peaks, and subsequently sequenced following trypsin digestion to identify and 
characterize the protein-like compound(s) in the CSF that contribute to chronic 
pain. 
The chromatograms that were obtained from HPLC of pooled 
osteoarthritis CSF and pooled pain-free control CSF differed very distinctly in 
two areas (Figure 4-5). Interestingly, the two distinct peaks corresponded to 
peaks C and O that were able to trigger IL-6 release in T98G cells (Figure 4-3). 
The corresponding peaks from each HPLC separation have been manually 
collected and will also be subjected to mass spectrometry to identify the 
difference in characteristics of the protein-like substance(s) in the CSF of 
osteoarthritic pain patients and the CSF of pain-free controls. Differences in 
amino acid concentrations between CSF of chronic pain patients and pain-free 
patients have been investigated using HPLC recently. Amino acids like D-serine, 
glycine, aspartate, tyrosine and valine were demonstrated to be significantly 
higher in the CSF of chronic pain patients than in the CSF of pain-free controls 
(Tachibana et al., 2005; Sethuraman et al., 2007). In this project, further analysis 
was carried out to study the difference in composition of protein-like substances 
in the CSF of the two patient groups. Future mass spectrometry identification and 
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characterization of these substances in the CSF of chronic pain patients, which are 
otherwise not found in that of pain-free controls, would greatly benefit the 
understanding of the mechanisms behind chronic pain. 
 The patients involved in this study had undergone local anaesthesia with 
subcutaneous administration of lignocaine (3-4 mL of 1% lignocaine) just before 
the i.t. CSF collection. As it is possible that the tip of the spinal needle, traversing 
through the area previously infiltrated with lignocaine, could have been 
contaminated with traces of lignocaine, IL-6 releasing activity of T98G cells 
when exposed to lignocaine was analyzed. Different concentrations of lignocaine 
(up to a high concentration of 5 mg/mL) were not able to trigger IL-6 release in 
T98G cells. Hence we can safely conclude that the IL-6 releasing activity and the 
peaks obtained from HPLC were not due to the presence of lignocaine. 
 The total protein concentration of CSF is very low (CSF/serum ratio of 
protein concentration is approximately 0.004), and it is dominated by a small 
number of highly abundant proteins. Albumin is the most dominant protein in 
CSF, accounting for over 60% of the total protein content (Huhmer et al., 2006). 
In addition to lignocaine, we analyzed the IL-6 releasing activity of T98G cells 
when exposed to different concentrations of albumin. At albumin concentrations 
up to 0.1 mg/mL, no IL-6 was released. However at high concentrations of 1 and 
10 mg/mL, there was IL-6 release in the T98G cells. As the upper limit of 
albumin in normal human CSF is 0.5 mg/mL (Roos, 2005), we can safely 
conclude that the contribution of albumin present in the patients’ CSF to IL-6 
release in T98G cells is negligible. 
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The concentration of various pain-related proteinous substances or their 
precursors and processed forms may be up or down-regulated in chronic pain 
patients’ CSF. In this chapter, fractions of chronic pain patients’ CSF that contain 
protein-like substances that contribute to chronic pain have been successfully 
isolated. These substances purified from CSF could have important 
pathophysiological roles related to mechanisms of chronic pain perception. They 
may be potential markers for chronic pain, and could lead to the future 











Signaling Mechanism of Chronic Pain in 
the T98G Cell System  
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5.1 Objectives of Chapter 
The intracellular signaling pathway that leads to the perception of chronic 
pain has been a key interest in pain research. Attempts were made to investigate 
the signaling mechanism that is triggered by the CSF of chronic pain patients, 
which eventually causes IL-6 release from T98G cells.  
Besides pro-inflammatory cytokines like IL-6, many other substances are 
involved in the mechanism of chronic pain, as reviewed in Chapter 1. Nuclear 
factor-kappa-B (NF-κB), a protein complex that enters the nucleus and controls 
DNA transcription, is known to play a role in chronic pain perception (Fu et al., 
2007; Meunier et al., 2007). NF-κB signaling is also known to activate IL-6 gene 
transcription in tissue injury and inflammation (Libermann and Baltimore, 1990). 
Attempts were made to investigate the possibility that NF-κB activation affects 
the IL-6 release from T98G cells upon exposure to osteoarthritis patients’ CSF. 
NF-κB inhibition studies and western blot to identify NF-κB activation were 
carried out to test this hypothesis.  
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5.2 Materials and Methods 
5.2.1 Materials 
Bay 11-7082 was obtained from Sigma Aldrich (St Louis, MO, USA). The 
cell fractionation kit (NF-κB Activation Assay Kit) was obtained from 
FIVEphoton Biochemicals (San Diego, CA, USA). The total cell lysis buffer 
(CelLytic MT mammalian tissue lysis/extraction reagent) was obtained from 
Sigma Aldrich (St Louis, MO, USA). Dithiothreitol (DTT) was from the NF-κB 
Activation Assay Kit. Protease inhibitors pepstatin A, leupeptin, aprotinin were 
purchased from Applichem (St Louis, MO, USA) and phenylmethylsulfonyl 
fluoride (PMSF) was from Sigma Aldrich (St Louis, MO, USA). 
 Rabbit anti-p65 antibody and goat anti-rabbit IgG-horseradish peroxidase 
(HRP) were from the NF-κB Activation Assay Kit (FIVEphoton Biochemicals, 
San Diego, CA, USA). Mouse anti-actin antibody was obtained from Merck 
Millipore (Billerica, MA, USA) and goat anti-mouse IgG-HRP was from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Tween-20 was obtained from 
Promega (Madison, WI, USA). Pierce ECL Western Blotting Substrate was 
purchased from Thermo Fisher Scientific (Pittsburgh, PA, USA). 
 
5.2.2 CSF Samples 
CSF from pain-free patients and osteoarthritis patients were collected as 
described in Chapter 2 (Section 2.2.2, Page 33) and Chapter 3 (Section 3.2.2, 
Page 51). For the NF-κB activation study using western blot, pooled osteoarthritis 
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patients’ CSF and pooled pain-free patients’ CSF were used. The CSF was pooled 
as described in Chapter 4 (Section 4.2.2, Page 65). 
 
5.2.3 Cell Culture and NF-κB Inhibition 
T98G cells were seeded on 24-well plates. To investigate the effect of NF-
κB inhibition on IL-6 release in T98G cells, the cells were incubated with 
different concentrations of NF-κB inhibitor Bay 11-7082 (0 – 10 µM) for 1 h. 25 
µL or 50 µL of CSF from osteoarthritic pain patients or CSF from pain-free 
controls was then added to the cells, and the cells were incubated for 48 h at 37°C 
in a fully-humidified incubator. The supernatant was then collected and analyzed 
for IL-6 using ELISA as described in Chapter 2 (Section 2.2.4, Page 34). The IL-6 
detected in the control samples (cell culture without CSF and Bay 11-7082 added) 
was subtracted from the raw values to obtain the final values to be plotted in the 
figures. 
 
5.2.4 Cell Fractionation and Cell Lysis 
T98G cells were cultured on 10-cm
2
 culture dishes until they were 80-90% 
confluent. The EMEM in each dish was aspirated and the dish was washed with 
PBS twice. The cells were then incubated with 800 µL of pooled CSF from either 
osteoarthritis patients or pain-free patients in FBS-free EMEM (total volume 8 
mL) for 24 h at 37°C in a fully-humidified incubator.  
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The cells were then fractionated into cytoplasmic and nuclear fractions 
according to the manufacturer’s instructions. EMEM was removed and the culture 
dishes were washed with PBS and placed on ice. The cells were covered with 500 
µL of ice cold Cytoplasmic Fractionation Reagent (CER-1) with protease 
inhibitors and DTT, kept on ice for 5 min, and removed using a cell scraper. They 
were placed in 1.5 mL tubes and centrifuged at 2500 rpm for 3 min at 4°C. The 
supernatant was collected as the cytoplasmic fraction. The pellet was re-
suspended in 500 µL of ice cold CER-1 with protease inhibitors and DTT, the 
tubes were placed in ice for 5 min, and then centrifuged again at 2500 rpm for 3 
min at 4°C. The supernatant was discarded and 60 µL of ice cold Nuclear 
Fractionation Reagent (NER-1) with protease inhibitors was added to the pellet. 
After vortexing for 1 min and placing the tubes in ice for 10 min, they were 
centrifuged at 16,000 rpm for 10 min at 4°C. The supernatant was collected as the 
nuclear fraction. 
To collect total cell lysate, the cells were covered with 500 µL of ice-cold 
CelLytic MT mammalian tissue lysis/extraction reagent and incubated on a shaker 
for 15 min. The cells were removed using a cell scraper, placed in 1.5 mL tubes 
and centrifuged at 16,000 rpm for 10 min at 4°C. The supernatant was collected 
as total cell lysate. Total cell lysates, cytoplasmic fractions and nuclear fractions 




5.2.5 Western Blot 
Total cell lysates, cytoplasmic fractions and nuclear fractions were 
separated by gel electrophoresis using 10% sodium dodecyl sulfate-
polyacrylamide gel and transferred to polyvinylidene difluoride (PVDF) 
membranes. Membranes were blocked in 10% w/v non-fat dry milk in PBS with 
0.1% v/v Tween-20 (PBST) for 1 h, and probed with one following antibodies: 
rabbit anti-p65 (1:400) and mouse anti-actin antibodies (1:500) at 4°C overnight. 
After washing three times in PBST buffer, membranes were incubated with goat 
anti-rabbit IgG-HRP (1:3000) or goat anti-mouse IgG-HRP (1:2000) for 1 h at 
room temperature. After washing three times in PBST buffer, detection was 
performed using Pierce ECL Western Blotting Substrate and analyzed by 
Molecular Imager Gel Doc XR System (Bio-Rad, Hercules, CA, USA). 
Densitometry analysis was performed using the Molecular Imager Gel Doc 
software. 
 
5.2.6 Statistical Analyses 
All data are expressed as mean ± SEM. SPSS 18.0 for Windows (IBM, 
Chicago, IL) was used for analyses. One-way ANOVA with Bonferroni post hoc 
test was used for multiple comparisons of IL-6 releasing activities of osteoarthritis 
and control CSF in the presence of different concentrations of Bay 11-7082. One-
way ANOVA with Bonferroni post hoc test was also used for multiple 
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comparisons of p65 relative intensity between cells only, osteoarthritic pain and 






5.3.1 Inhibition of NF-κB led to Reduced IL-6 Release in T98G Cells 
 Different concentrations of NF-κB inhibitor Bay 11-7082 was added to the 
T98G cells prior to addition of osteoarthritis or pain-free patients’ CSF. IL-6 
release was reduced in a concentration-dependent manner when increasing 
concentrations of Bay 11-7082 were added to the cells before exposure to CSF of 














Figure 5-1 Effect of NF-κB inhibitor Bay 11-7082 on IL-6 release in T98G 
cells upon addition of osteoarthritis CSF. IL-6 release from T98G cells treated 
with osteoarthritis patients’ CSF was reduced in a concentration-dependent 
manner in the presence of Bay 11-7082. 0 – 10 µM Bay 11-7082 was added to 
T98G cells on 24-well plates 1 h before addition of 25 µL or 50 µL CSF. IL-6 
levels in the cell supernatant were measured after 48 h by ELISA. 5 osteoarthritis 
patients’ CSF were analyzed. Mean ± SEM, + p < 0.05 using one-way ANOVA 
with Bonferroni post hoc test, 0 µM Bay 11-7082 vs corresponding higher 
concentrations of Bay 11-7082 using 25 µL CSF; * p < 0.05 using one-way 
ANOVA with Bonferroni post hoc test, 0 µM Bay 11-7082 vs corresponding 
higher concentrations of Bay 11-7082 using 50 µL CSF. 



































































 When T98G cells were exposed to Bay 11-7082 and subsequently 
triggered with pain-free patients’ CSF, IL-6 release was less than that when 
triggered with osteoarthritis patients’ CSF. IL-6 release was also reduced in the 
presence of Bay 11-7082, but the concentration-dependent reduction was not 





















Figure 5-2 Effect of NF-κB inhibitor Bay 11-7082 on IL-6 release in T98G 
cells upon addition of control CSF. IL-6 release from T98G cells treated with 
pain-free control patients’ CSF was reduced in the presence of Bay 11-7082, but 
the concentration-dependent reduction was not significant. 0 – 10 µM Bay 11-
7082 was added to T98G cells on 24-well plates 1 h before addition of 25 µL or 
50 µL CSF. IL-6 levels in the cell supernatant were measured after 48 h by 
ELISA. 5 control patients’ CSF were analyzed. Mean ± SEM, + p < 0.05 using 
one-way ANOVA with Bonferroni post hoc test, 0 µM Bay 11-7082 vs 
corresponding higher concentrations of Bay 11-7082 using 25 µL CSF; * p < 0.05 
using one-way ANOVA with Bonferroni post hoc test, 0 µM Bay 11-7082 vs 
corresponding higher concentrations of Bay 11-7082 using 50 µL CSF. 
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5.3.2 NF-κB Activation in T98G Cells Upon Exposure to CSF of Chronic 
Pain Patients 
The NF-κB activation assay kit makes use of the translocation of NF-κB 
transcription factor subunit p65 into the nucleus to measure the amount of NF-κB 
activation. Western blot was carried out on total cell lysate, cytoplasmic fractions 
and nuclear fractions of T98G cells exposed to patients’ CSF. Both T98G cells 
alone and T98G cells exposed to pain-free controls’ CSF for 24 h had low levels 
of p65 in the nuclear fraction as compared to cytoplasmic fraction. Cells exposed 
to chronic pain patients’ CSF for 24 h, on the other hand, showed much higher 
levels of p65 in the nuclear fraction as compared to the cytoplasmic fraction 




Figure 5-3 Western blot demonstrating NF-κB activation. T98G cells treated 
with osteoarthritis CSF showed NF-κB activation, in contrast to cells treated with 
control CSF. (A) T98G cells were exposed to 3 different treatments for 24 h: no 
CSF (cells only), osteoarthritic pain CSF and control (pain-free) CSF. The cells 
were fractionated into total cell lysate, cytoplasmic and nuclear fractions and 
subjected to western blot using anti-p65 antibodies. Coimmunodetection of actin 
was carried out to ensure equal loading of samples. (B) Quantification of the 
western blot. Data were normalized to control (cells only, total cell lysate), n=3. 
Mean ± SEM, 
+
 p < 0.05 using one-way ANOVA with Bonferroni post hoc test, 
osteoarthritic pain vs pain-free, using cytoplasmic fraction samples; * p < 0.05 
using one-way ANOVA with Bonferroni post hoc test, osteoarthritic pain vs pain 




 The role of glial NF-κB in pain has emerged in recent years. Knockout of 
NF-κB subunit p50 in mice reduced acute and inflammatory nociception 
(Niederberger et al., 2007). Lentiviral delivery of IκB-α, inhibitor of NF-κB, 
injected into the dorsal horn inhibited the expression of pain mediators including 
pro-inflammatory cytokines, hence reducing pain (Meunier et al., 2007). The NF-
κB pathway was shown to contribute to neuropathic pain in rat CCI models and 
also a model of CRPS (de Mos et al., 2009). 
The promoter region of the IL-6 gene has a putative NF-κB binding site. 
Libermann and Baltimore (1990) found that a fragment of the IL-6 promoter 
region specifically binds to NF-κB protein, and mutations to the specific site 
abolished the interaction. This suggests the importance of NF-κB as a mediator 
for IL-6 gene expression and activation. In a rat CCI neuropathic pain model, IL-6 
expression was also demonstrated to be upregulated through the NF-κB pathway 
(Lee et al., 2008). 
It would be interesting to know whether the signaling pathway of IL-6 
release in T98G cells involved the actions of NF-κB. This was investigated firstly 
by pre-treating the cells with different concentrations of selective NF-κB inhibitor 
Bay 11-7082 before triggering them with patients’ CSF. True enough, IL-6 
release from the cells were reduced in a concentration-dependent manner in the 
presence of Bay 11-7082, for the chronic osteoarthritic pain group. IL-6 release 
was also reduced for the pain-free control group but the reduction did not follow 
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the same trend as that of the chronic pain group. The reduction of IL-6 release 
upon pre-treatment of Bay 11-7082 indicates that the NF-κB protein was indeed 
involved. This finding suggests that the presently unknown protein-like 
substance(s) in the chronic pain patients’ CSF makes use of the NF-κB pathway 
to trigger IL-6 release from T98G cells. 
To further confirm that NF-κB is activated in the presence of CSF from 
chronic pain patients, an NF-κB activation assay kit, which utilizes western blot to 
detect NF-κB activation, was used. After exposure to stimuli that elicits the NF-
κB pathway, the inhibitory subunit of NF-κB is phosphorylated and degraded, 
exposing nuclear targeting signals on NF-κB transcription factor subunit p65, 
which translocates into the nucleus and binds regulatory elements that control 
gene transcription. The NF-κB activation assay kit works by quantitating the 
nuclear import of p65. Elevated levels of p65 in nuclear fractions relative to other 
cellular fractions indicate NF-κB activation. The western blot of total cell lysate, 
cytoplasmic fraction and nuclear fraction of the 3 groups (cells only, cells 
exposed to osteoarthritic pain patients’ CSF and cells exposed to pain-free 
patients’ CSF) showed NF-κB activation in the osteoarthritic pain group but not in 
the cells only and pain-free group. This finding confirms that NF-κB is activated 
upon addition of chronic pain patients’ CSF, and together with the NF-κB 
inhibition study done earlier, shows that it acts upstream of IL-6 in this in vitro 
T98G cell system. 
A study by Ichiyama et al. in 2002 demonstrated elevated levels of NF-κB 
activation in CSF cells in patients with meningitis, and this was positively 
  
101 
correlated with CSF IL-6 concentration, suggesting that NF-κB activation in 
meningitis leads to the production of pro-inflammatory cytokines. In this chapter, 
we have successfully established that NF-κB plays a role in IL-6 release from 
T98G cells upon exposure to CSF from chronic pain patients. Besides IL-6, which 
we have established as a marker for chronic pain in an in vitro system, NF-κB 
activation in T98G cells can also be a potential marker for evaluating the extent of 
chronic pain in patients. 
As NF-κB is just one of many signaling molecules that are known to be 
involved in chronic pain mechanisms and IL-6 activation, it is worthwhile to 
study other pain-related substances either upstream or downstream of NF-κB. 
Protein kinase A (PKA) and PKC are two such molecules that are known to 
regulate IL-6 gene expression (Gadient and Otten, 1997). PKC, in particular, was 
suggested to act upstream of NF-κB in the signaling pathway resulting in IL-6 
release in glioma cells (Zumwalt et al., 1999). Prostaglandins are also known to 
regulate pain and are shown to act downstream of NF-κB (Ackerman et al., 2008). 
Figure 5-4 shows a possible signaling pathway in which IL-6 is released in T98G 
cells. It would be of great interest to investigate whether molecules like PKC and 
prostaglandins are involved in IL-6 release in T98G cells, in order to obtain a 
clearer representation of how chronic pain patients’ CSF trigger the release of IL-











Figure 5-4 Possible signaling pathway of IL-6 release in T98G cells. CSF of 
chronic pain patients contains protein-like substances that activate T98G cells to 
release IL-6. PKC may be activated upstream of NF-κB, and prostaglandins may 











 Chronic pain is a major healthcare problem due to its negative impact on 
work performance and daily activities. Effective therapeutics for chronic pain 
requires targeting the cellular mechanisms that individually or collectively 
produce pain, instead of targeting superficial symptoms. Hence, studying the 
mechanisms underlying chronic pain and the search for potential targets for 
chronic pain treatment have become top priority in pain research in recent years. 
The importance of biological markers in chronic pain research is apparent, be it in 
assessing the degree of chronic pain, in enabling the early diagnosis of pain-
related diseases, or in predicting the outcome of pain treatment. There are no 
reports on in vitro markers that may aid in chronic pain research at present. In this 
pursuit in understanding the complex mechanisms of chronic pain, this study 
focused on establishing an in vitro biological marker that may aid in the 
management of chronic pain, and also on isolation and identification of 
substances involved in chronic pain. 
 The first objective of the study was to investigate pro-inflammatory 
cytokine release in a T98G cell culture system as a potential marker for chronic 
pain. IL-6 release from T98G cells was found to be elevated upon exposure to 
CSF of chronic pain patients as compared to CSF of pain-free controls. IL-6 
release was also elevated upon exposure to CSF collected before steroid therapy 
as well as upon exposure to CSF of patients whose steroid therapy was ineffective. 
IL-6 release upon exposure to CSF of patients whose therapy was effective was 
attenuated completely when in vitro steroid was added to the cell culture. All 
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these results showed the effectiveness of IL-6 release in the T98G cell culture 
system upon addition of CSF as in vitro biological marker for chronic pain.  
 The second objective of the study was to fractionate and isolate pain-
related substances in the CSF and to establish the signaling pathway involved in 
chronic pain. CSF from chronic osteoarthritic pain patients was fractionated by a 
two-step HPLC procedure, using the previously established cell culture system to 
analyze the IL-6 releasing ability of each peak. Three peaks that could trigger IL-
6 release in T98G cells were isolated and collected at the end of the procedures. 
The HPLC chromatogram of chronic pain CSF was compared against that of pain-
free control CSF and the peaks that showed differences were also collected. We 
have effectively isolated fractions of chronic osteoarthritic pain CSF that contain 
protein-like substances that could contribute to chronic pain. In addition, in 
investigating the possible signaling mechanism that leads to the IL-6 release, it 
was found that exposure to chronic osteoarthritic pain CSF led to NF-κB 
activation in T98G cells and this activation acts upstream of IL-6. 
 In summary, the present results of the study demonstrate another 
perspective in chronic pain research. Utilizing CSF of chronic pain patients, IL-6 
have been successfully established as an in vitro biological marker that can 
provide an objective evaluation of the extent of chronic pain, which is an 
advantage over subjective methods such as pain score measurements, and also to 
predict an individual’s response to i.t. steroid therapy. The isolation of fractions 
from chronic osteoarthritic pain CSF that can trigger IL-6 release paves a way for 
the identification and characterization of pain-related substances in the CSF. 
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These collected fractions, after analysis by mass spectrometry, would provide 
highly useful and detailed information on the protein-like substances in the CSF 
that contribute to chronic pain. Establishing that CSF of chronic pain patients 
trigger NF-κB activation in T98G cells upstream of IL-6 is the first step towards 
elucidating the mechanisms behind IL-6 release in this T98G cell system. NF-κB 
could be yet another useful in vitro biological marker for the objective assessment 
of chronic pain. 
 
6.2 Limitations of Study 
 The study involves in vitro work using T98G cells as an astrocytic model. 
The disadvantage of in vitro studies is that it is difficult to extrapolate the results 
achieved from in vitro studies to the actual physiology of humans. The results 
obtained using T98G cells could not be replicated using primary astrocytes. As 
such, the IL-6 release from T98G cells acts uniquely as a read-out, providing an 
unbiased assessment of the extent of chronic pain in patients. 
Another limitation of our study was that due to difficulties in obtaining 
more CSF samples, we were only able to focus on two conditions related to 
chronic pain: PHN and osteoarthritis. In addition, due to the lack of more PHN 
CSF samples, isolation of pain-related protein-like substances using HPLC could 
only be carried out on osteoarthritis CSF samples. Encompassing more chronic 
pain conditions in our study would widen the scope of our work. Comparisons can 
be made between various pain conditions, thereby establishing a more complete 
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picture of the relationship between substances in the CSF and the perception of 
chronic pain due to different conditions. 
 
6.3 Future Directions 
 The separation and purification of chronic pain patients’ CSF into 
different fractions is just the first step in the characterization of substances 
involved in chronic pain. More in depth studies have to be performed on these 
purified fractions. MALDI-TOF mass spectrometry would be the next step to 
determine the molecular weight of the peaks, and the peaks would be 
subsequently sequenced to identify and characterize the protein-like substances in 
the CSF that play a role in chronic pain. Subsequently, these substances could be 
isolated and animal bioactivity studies carried out to determine the pain 
perception mechanisms of these substances. 
 Further work should also be carried out on the signaling mechanism of IL-
6 release. Identification of NF-κB activation as upstream of IL-6 release is only 
the first step in unraveling the signaling mechanism of chronic pain in this T98G 
cell system. Other substances known to be involved in IL-6 activation and chronic 
pain mechanisms should also be analyzed. 
 Due to the relatively invasive nature of obtaining CSF from patients as 
well as the limited amount (2 mL) that can be withdrawn at any one time, it would 
be beneficial if a substitute that is more easily obtained can be used in place of 
CSF. It was demonstrated that the concentration of 13 amino acids in CSF was 
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directly related to the plasma concentration in normal individuals (McGale et al., 
1977). Levels of serum and CSF glucose were also positively correlated in 
children (Nigrovic et al., 2012). It would be worthwhile to investigate the 
correlation between chronic pain patients’ serum and CSF on their ability to 
trigger IL-6 release in T98G cells. If there is a correlation, this method would 
potentially serve as a valuable analytical tool in the assessment of chronic pain, 
and more chronic pain conditions could be studied as well, as human serum 
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